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EXECUTIVE SUMMARY 
It is widely accepted that reimbursement policies and practices are important considerations in the 
research and development (R&D) decisions of potential innovators of healthcare technologies, and the 
investors who finance them. Experts broadly concurred that reimbursement is one of the factors that 
determines which products in development eventually make it to market, as well as the level of access 
to those products and use by care providers and patients. This, in turn, can affect product development 
and innovation. However, reimbursement is not necessarily among the most important drivers in every 
circumstance and likely plays different and evolving roles with respect to drugs and devices. Scientific 
discoveries and perceptions of clinical need may be the most important factors influencing innovation.  
It is also widely held that decentralized decision-making, the absence of government-regulated pricing, 
and lack of restrictions on reimbursement create an environment that is generally conducive to greater 
R&D expenditure. Without price controls and reimbursement limits, firms are able to invest in drug 
development with fewer concerns about future market access and reimbursement levels once their 
product is approved. But, more expenditure on R&D does not necessarily give rise to more innovation 
that improves consumer welfare (as defined in this project), as more spending in the drug and device 
development pipeline may not yield products offering value concurrent with the benefits conferred. The 
appropriate question, therefore, is not how much is spent on R&D (i.e., the enterprise), but how to 
measure the benefits to patients, payers, and society of the resultant drugs and devices that are brought 
to market.1  
Payers account for a large share of the purchases of healthcare technologies.2 Consequently, the 
decision by a public program or health plan to subsidize use of a technology (often referred to as a 
coverage decision) is a critical determinant of expected, and actual, return on investment (ROI) for 
developers and investors. The level and method of payment selected and any policies or practices 
defining the circumstances under which the healthcare technology is reimbursed serve as (lesser) 
determinants. In making these reimbursement decisions, payers make formal and informal evaluations 
of the value that drugs and devices confer. By doing so, they may establish a market that is more 
conducive to rational, value-based consumer decisions. 
It is thus important to understand how reimbursement affects actual or expected ROI, and by extension, 
how ROI may impact innovation, as developer and investor assessments of the market viability of a new 
                                                          
1




 An estimated 75-80% of the costs of biopharmaceuticals are borne by payers, according to Kaiser Family 
Foundation calculations (2008) using National Health Expenditure historical data from the Centers for Medicare 
and Medicaid Services (https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-
Reports/NationalHealthExpendData/index.html?redirect=/NationalHealthExpendData); unfortunately, there is 
relatively little data available pertaining to insurance cost share for medical devices. 
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product take into account payers’ potential actions (e.g., would it be covered, at what payment level, 
and with which conditions?). It is also important to identify any potential downstream effects that 
reimbursement may have on innovation over the long-term, as use of specific reimbursement 
approaches grows or fades. The objective of this research project was to describe current 
reimbursement methods and analyze their impacts (if any) on drug and device use and innovation. Our 
findings incorporate assessments of the effects of reimbursement on innovation based on economic 
theory, literature reviews, and consultation with experts. 
We identified key characteristics of reimbursement methods and selected five of these for closer 
analysis to determine how they affect factors that contribute to ROI such as pricing, utilization, and 
provider and patient decision-making. These characteristics were: 
 The reimbursement decision-making process: how payers make decisions on which drugs, 
devices, and other healthcare technologies to make available to patients, at what price, and for 
whom;  
 Product categorization and differentiation: how payers distinguish between the drugs or devices 
that they cover; 
 Method of payment: the terms under which a payer makes reimbursement to a provider; 
 Method of defining the payment amount: the methods used to establish the amount the third-
party payer will reimburse a provider or supplier furnishing a healthcare technology to a patient, 
and; 
 Patient cost sharing: out-of-pocket costs borne by consumers, net of insurance coverage, when 
they obtain services or purchase prescription drugs, durable medical equipment (DME), or other 
health technologies. 
Key drivers of the use of different reimbursement methods include state and federal statutes and 
regulations for public payers such as Medicare and Medicaid; availability of detailed reimbursement 
information and methodologies for public plans – but generally not private payers – as potential 
benchmarks; and competition among private payers. Cost containment also appears to be an important 
factor driving payer choices.  
We then assessed whether and, if so, how the aforementioned characteristics of reimbursement 
methods affect incentives to innovate in drugs and devices in qualitative (direction and relative 
magnitude of impact) terms. We classify innovations as incremental, substantial, or radical, depending 
on the significance of the unmet need addressed and the extent of additional benefit (comparative 
effectiveness) offered relative to existing treatments. Incremental innovations offer small gains in one or 
both of these areas. Radical innovations address significant unmet needs and provide significant 
additional benefits, while substantial innovations either address significant unmet needs or provide 
significant additional benefits – but not both. 
The analytical framework that we developed for this purpose posits that reimbursement policies and 
practices can impact product developers’ ROI directly in three ways. The first is by establishing a specific 
payment level, which in turn affects average sales price. The second is by setting a volume of sales at 
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that payment level. The third is by influencing seller costs associated with development, manufacture, or 
sale of a healthcare technology. Our framework also posits that reimbursement policies indirectly 
influence ROI by establishing different incentives for key actors, including patients/consumers, 
dispensers, providers, sellers, and payers. In turn, these incentives impact effective sales price, sales 
volume, and in some cases, sellers’ costs of development, manufacturing, and sales. Together these 
factors determine the revenues and profits to be derived from the product, important determinants of 
the ROI for the developer and investors. 
Prospective innovators take into account expectations of the impact of current and anticipated 
reimbursement policies and practices when deciding to invest in R&D, and in directing investments to 
particular products. A positive ROI rewards successful innovators and will, in theory, spur the next 
generation of investment. We assume that larger expected returns on investment provide more 
incentives to invest in development of novel healthcare technologies, as well as development of new 
evidence supporting novel uses of existing healthcare technologies.  
Figure S1 identifies the primary pathways through which the five aforementioned characteristics of 
reimbursement policies and practices influence ROI. Although there are direct paths of influence, the 
connections are not direct in most cases. The distribution systems for healthcare technologies involve 
many actors and intermediaries whose actions affect ROI for manufacturers, and influence the 
reimbursement policies and practices used by payers. This complexity makes effects harder to 
determine and often ambiguous.  
Table S1 summarizes our assessments of the direction and magnitude of effects on innovation from 
each reimbursement characteristic. The primary takeaway is that it remains unclear precisely how 
reimbursement policies and practices ultimately affect innovation. We found no empirical evidence to 
directly connect reimbursement policies and practices with the quantity or quality of healthcare 
technology innovation produced, so our conclusions are frequently drawn from economic theory. 
The U.S. retains a pluralist framework with regard to the reimbursement decision-making process – 
hundreds of payers use their own assessment approaches to reach their judgments, leading to 
considerable variation. The lack of uniform decision-making weakens the ability of all but the largest 
payers to motivate developers. The effects of different decision-making processes are hard to trace. 
Theoretically, processes that are transparent and evidence-based will provide the clearest signals to 
developers and favor development of products that address unmet needs and/or provide added value 
over existing therapies. 
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Figure S1: Pathways through which reimbursement characteristics affect ROI 
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Table S1: Effects on innovation attributable to reimbursement characteristics 




Effects due to decision-making processes are unclear, although specific components or 
outcomes of these processes, such as payment, product categorization, and cost 
sharing, may have more discernable effects (described below). In theory, decision-
making processes that are transparent and evidence-based are more likely to foster 
innovation that enhances consumer welfare by sending clearer signals to developers 
about the types of products that payers place more value on, and how they assess that 
value. Timeliness and consistency in decision-making processes may also help by 
reducing developers’ and investors’ level of uncertainty about the likelihood of payers 




Empirical evidence is limited concerning the effects on ROI or innovation from the 
approaches to product categorization or differentiation used by payers. In theory, 
approaches that distinguish products based on value are more likely than 
administrative approaches to promote investment in and development of products 
that are clinically and cost-effective and address areas of unmet need.  
Method of payment  With per-unit payments, effects on innovation largely depend on the method used to 
determine payment amounts, as discussed in the next panel of this table. With 
bundled payment, effects on innovation are uncertain. Radical innovations are unlikely 
to be affected by bundled payments because of the level of benefits they provide and 
the likelihood that they will be paid as an add-on to the bundle. At the same time, 
there may be significant disincentives for incremental innovations, unless they are 
cost-reducing. Effects of bundled payment on substantial innovations, which fall 
between radical and incremental innovations, are unclear. 
Method of defining 
payment amount  
External benchmarking, a process of defining a payment level based on the sales price 
in the market or markets in which the product is sold, or an estimate of the provider's 
acquisition cost, is likely to increase ROI and incentives to innovate, compared to other 
approaches used to define payment amounts. The effects of internal benchmarking, or 
defining a payment level based on what is paid for comparable covered products for 
which the payer has already established a payment amount, are largely unclear, but it 
is most likely that this approach will reduce ROI and incentives to innovate. Value-
based approaches are the most promising for yielding effects on ROI that reflect 
products’ benefits relative to their costs (judged from consumer, payer, and/or 
societal perspective). Effects of lowest possible price strategies are unclear, but this 
approach may over-incentivize investment in incremental innovations and under-
incentivize investment in radical innovations. 
Patient cost sharing Although there is substantial evidence that cost sharing affects utilization, cost sharing 
seems unlikely to have substantial effects on ROI or incentives to develop or invest in 
innovative products. Patient demand for innovative products is likely to be relatively 
inelastic, especially for radical innovations. Coinsurance may lead to greater effects 
compared to fixed copayments, especially for high-cost products, but it still seems 
unlikely to have significant effects on innovation. Manufacturers’ programs that help 
patients with their cost sharing further limit potential effects. 
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There is limited evidence concerning the effects of different approaches to product categorization and 
differentiation. Theoretically, evidence-based and value-based approaches offer the potential to have a 
positive impact on innovation, and interest in value-based insurance designs continues to grow. The 
unique nature of the U.S. healthcare system, with its multitude of payers and lack of central decision-
making, offers challenges for implementation of value-based approaches, such as reaching agreement 
on what constitutes “value.” Our case study of the Premera Blue Cross value-based formulary pilot 
program highlights some additional challenges, including difficulties in getting access to information 
needed to assess value and measuring benefits to patients. 
While payment methods vary, the fundamental distinction is whether payers compensate providers or 
suppliers of healthcare technologies on a per-unit basis or as part of a bundled payment for a package of 
goods and services used for a clinically-defined episode of care. Per-unit payments seem unlikely to 
favor development of any particular type of innovation, but may also be ineffective at discouraging 
development of non-innovative products. A shift to bundled payments from per-unit payments may 
incentivize development of cost-reducing products (from the perspective of the payer), but may 
discourage incremental innovations. 
Payers currently are more likely to rely on external and internal price benchmarking, rather than value-
based pricing, to establish payment amounts. Experts consulted for this project also noted that unit 
costs and budget impact play a role in other policies, such as patient cost sharing and use of utilization 
management tools (e.g., prior authorization). Theoretically, broader use of value-based or outcomes-
based reimbursement would lead to lower returns on products and services offering little value added, 
higher returns for products with higher value, and greater clarity about where the value-added is 
uncertain. Our case study of the performance-based risk-sharing agreement for Velcade in the U.K. 
illustrates some of the administrative and measurement challenges in establishing performance-based 
payment. 
The effects of reimbursement policies and practices on innovation may also be muted by the ability of 
developers to strategically price their products. Manufacturers’ pricing models take into account 
expectations about lost sales due to higher costs or cost sharing; complex and secretive rebate and 
discounting mechanisms favor high list prices; and cost sharing offset programs reduce the negative 
effects on demand when payers apply patient cost sharing. Patient cost sharing does not appear to be 
an important barrier to innovation at present, at least for substantial or radical innovations. However, 
with growing levels of patient cost sharing, broader use of coinsurance, and very high list prices for new 
products, the balance may tip if utilization drops more than manufacturers anticipate or can 
compensate for with cost-sharing offset programs, or if manufacturers lose pricing power.   
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INTRODUCTION 
There is a long-standing belief that the extent and nature of product reimbursement is a significant 
factor in the development decisions of potential innovators of healthcare technologies such as drugs, 
biologics, vaccines, and medical devices, and of the investors who finance them. Analysts posit that 
payers influence the entry of new products into the market, and their policies have a substantial impact 
on research and development (R&D) decisions and whether companies choose to advance a technology 
to market.3 Experts consulted during this project not only agreed that reimbursement is an important 
factor in R&D and investment decisions, but also that its influence is growing in importance as the unit 
costs of many new products exceed the point at which third-party coverage is essential for individual 
affordability. They also noted that developers approach payers – especially CMS, but also private 
insurers – during development of new products to try to understand how (or if) a product would be 
covered, and how payments would be structured.  
It is less clear how reimbursement affects innovation. In setting out a conceptual model linking 
reimbursement and innovation, drawing on economic theory and relevant material from the literature, 
we established that reimbursement policy is one of many influences that affect the expected return on 
investment (EROI) for developers, investment decisions, and choices about how to direct research and 
development (R&D) resources (Figure 1).4 It is not necessarily among the most important drivers in 
every circumstance and may play different, and evolving, roles with respect to drugs and devices. Other 
measures, such as the concentration or volume of venture capital directed at specific developers or 
particular product areas, may be partial proxies for the amount and type of innovation being 
supported.5 
In most product markets, sellers set prices in response to perceived demand and willingness to pay by 
consumers. Two key problems confound healthcare technology markets. One is third-party payment, 
which makes consumers less sensitive to price. It also has an inflationary effect on both utilization and 
price. The second problem is that the physicians or health care organizations who act as decision makers 
on patients’ behalf may be insensitive to price at the point of prescribing or dispensing the product. 
They are also likely to be less sensitive to price than a consumer spending his or her own money. These 
market distortions can lead to excess consumption, as well as to consumption decisions that are 
inconsistent with the benefits or value a product offers in relation to available alternatives. For these 
                                                          
3
 Chambers, J., May, K., & Neumann, P. (2013). Medicare covers the majority of FDA-approved devices and Part B 
drugs, but restrictions and discrepancies remain. Health Affairs 32(6):1109-1115. 
4
 Bruen, B., Cohen, J., DiMasi, J., Docteur, E., Dor, A., Lopert, R., …, Shih, C. (2014).Task 3a deliverables: conceptual 
model, recommended characteristics for analysis, and analytical framework. Interim report for the Impact of 
Reimbursement Policies and Practices on Healthcare Technology Innovation project (Department of Health 
and Human Services' Contract# HHSP23320095635) 
5
 Ackerly, D.C., Valverde, A.M., Diener, L.W., Dossary, K.L., & Schulman, K.A. (2009).Fueling innovation in medical 
devices (and beyond): Venture capital in health care. Health Affairs, 28(1): w68-w75. 
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reasons, it falls to payers, through reimbursement policies, to offset market distortions by encouraging 
use of healthcare technologies in cases where the benefits justify the costs.  
Figure 1: Determinants of EROI in healthcare technology innovation 
 
Source: authors’ analysis 
While drug and device expenditures account for a relatively small share of health care expenditures, the 
absolute amounts are large, and their use can impact other health care costs. Reimbursement strategies 
and policies directly impact the amount spent on these new technologies, and so it is important to 
understand their impact on both the allocation of scarce national resources and the incentives that 
developers and investors have to invest in innovation. 
It is also important to understand the incentives that reimbursement policies and practices create, 
because they can differentiate rewards for products on the basis of assessed value, making them 
instrumental levers for encouraging valued types of innovation. Conversely, payers may use certain 
reimbursement policies and practices to limit use of novel technologies that fail to provide health 
benefits exceeding those offered by existing products (for example, by making them non-preferred 
products on a formulary). Or, they may set payment levels for these products that make them less 
expensive than existing products and therefore improve consumer welfare by reducing treatment costs. 
Experts consulted during this study agreed that reimbursement is one way payers signal what they value 
to potential innovators. There was a general sense that reimbursement is still a relatively “crude” signal, 
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RESEARCH OBJECTIVE AND QUESTIONS 
The objective of this research project was to describe current reimbursement methodologies and 
analyze their impacts on drug and device use and innovation, based on economic theory, review of 
literature, and expert consultation. The following research questions form the basis for this inquiry: 
• What are the key characteristics of reimbursement methods and how do they affect pricing, 
utilization, healthcare spending, and provider and patient decision-making? 
• What are the key drivers (statutes, social consensus, cost containment, etc.) of the use of 
different reimbursement methods? Do different payers have different goals? 
• How do the key characteristics of reimbursement methods affect innovation in drugs and 
devices? 
In addition, this research effort examined three specific reimbursement programs identified by experts 
consulted during this project as not widely used, but worthy of closer examination to see if they have 
the potential to encourage (or discourage) future innovation. These brief case studies address a final 
research question:  
• What are promising emerging reimbursement strategies to foster useful innovation that 
improves societal wellbeing? 
ORGANIZATION OF THE REPORT 
This report describes the findings from our analyses of key reimbursement characteristics and case 
studies. The methods section that follows describes our approach to the project, including definitions 
for key terms, development of a conceptual framework and analytic framework, and our approaches to 
gathering information through reviews of the literature, expert consultations, and studies of specific 
reimbursement approaches that experts viewed as potential drivers of incentives to innovate. The 
results section begins with a discussion of our framework, outlining the pathways through which 
reimbursement may influence innovation. This discussion is followed by a short introduction to five 
characteristics of reimbursement methods selected for analysis; further detail on these characteristics 
and factors that contribute to the use of different reimbursement methods is included in Appendix A. 
The majority of the results section focuses on how reimbursement strategies and policies may impact 
innovation through financial incentives, pricing, and multiplier effects. The results section includes key 
findings from our case studies; complete write-ups of each case are included as appendices B-D. The 
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METHODS & ANALYTICAL FRAMEWORK 
DEFINING KEY TERMS 
The project team developed working definitions of key project terms by assessing alternatives, based on 
definitions in common use in research and policy domains. 
REIMBURSEMENT 
For the purposes of the study, reimbursement is an umbrella term for the policies and practices that 
define the terms of coverage and payment for a healthcare technology. More specifically, 
reimbursement policies or practices encompass the implicit or explicit decisions of a health plan or 
public program that provides health insurance coverage (e.g., Medicare, Medicaid) – or actors, such as 
pharmacy benefit managers (PBMs), authorized to act on behalf of the plan or program with respect to 
healthcare technology decision-making – that:  
 Establish whether or not a healthcare technology is a benefit covered by the health plan or 
public program; 
 Define the terms under which a healthcare technology is covered; 
 Define the method of payment to the provider, dispenser or supplier of a healthcare 
technology;  
 Set or limit the amount the third-party payer will pay to the provider, dispenser or supplier of a 
healthcare technology, as well as the terms of any discounts or rebates supplied, or; 
 Set or limit any cost-sharing to be incurred by patients using the healthcare technology. 
PAYERS 
We use the term payers to refer to public health coverage programs and private health insurance plans. 
Payers are distinguished from purchasers in that they do not take possession of a drug or device, but 
instead compensate those who have purchased health-care technologies used by their beneficiaries or 
enrollees through the reimbursement policies and practices they adopt. PBMs that operate their own 
mail-order pharmacy services act as purchasers, as do hospitals and health systems like Kaiser 
Permanente and the Veterans Health Administration, which integrate the provision of coverage with the 
provision of care. 
Payers in the United States often employ subsidiaries to serve as managers of some or all health 
benefits. Examples include Medicaid managed care plans; Medicare Advantage plans; stand-alone 
Medicare prescription drug plans (PDPs); and PBMs. PBMs help design and administer drug benefits for 
public payers, private health plans, and self-insured groups (e.g., employers and organizations). The role 
of subsidiaries is important to take into account when analyzing the implications of reimbursement 
practices and policies employed by payers. Importantly, their widespread presence introduces 
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complications in analyzing the impact of payment methods on outcomes, in that subsidiaries tend to 
face incentives that differ from those of payers. 
Subsidiaries are often well-equipped and motivated to make decisions leading to savings in areas for 
which they are contractually responsible (e.g., pharmacy benefits), although the extent to which the 
savings are shared with, or passed on to, payers and consumers varies, depending on factors such as 
contractual terms and extent of competition among subsidiaries. Furthermore, depending on the terms 
of their contracts, subsidiaries may not benefit from any savings that accrue on the medical benefit side 
because of their decisions, and may be less motivated to make decisions that may involve higher up 
front expenditure but deliver downstream savings. A growing awareness of problems associated with 
subsidiary incentives have led to the creation of so-called “transparent model” PBMs that purport to 
pass through to the sponsor all negotiated discounts. These PBMs were estimated to account for 10% of 
the market in 2013.6 
INNOVATION 
The analytical focus of this study is healthcare technology innovation that enhances consumer welfare. 
Drawing upon a review of the relevant policy and research literature, we define an innovative healthcare 
technology as a new product that (a) meets a previously unmet or inadequately met health need and 
that (b) offers enhanced effectiveness in comparison with existing therapeutic alternatives. We describe 
a way to classify innovations as incremental, substantial, or radical, depending on the significance of the 
unmet need addressed and the extent of additional benefit (comparative effectiveness) offered. We 
further stipulate that healthcare technologies, innovative or not, can be said to enhance consumer 
welfare when they are offered at a price that is below the maximum price consumers would be willing 
to pay. In so doing, we take an approach that is consistent with the traditional economic concept of 
consumer surplus. 
Experts consulted during this project noted that the issue of who defines “innovation” is significant, as 
what is considered to be “innovative” can vary between the payer and the developer, and among 
payers. For example, one expert noted that payers may not view once-per-day drug dosing  as 
innovative compared to twice-per-day dosing unless health outcomes are better with the single dose, 
although some payers may view the once-per-day product as innovative if it reduces costs.  
Starting from a definition of innovation as “(the) development of new drugs or devices or evidence 
related to drugs or devices that improve consumer welfare,” we defined innovative products (drugs and 
devices) as those able to address diseases and conditions for which there is a substantive (i.e., non-
trivial) unmet or inadequately met need. We also defined a classification scheme for differentiating 
innovations in terms of the level and/or type of innovation they represent (Table 1). To arrive at this 
arrangement, we reviewed and assessed innovation classification schemes currently in use in drug and 
                                                          
6
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device regulation, pricing and reimbursement schemes, and in the academic literature. We designed the 
scheme to be consistent with our definition of innovation, reflective of the social welfare perspective 
adopted for this project, and to be useful in distinguishing the impact of various types of reimbursement 
characteristics and methods/strategies on motivations to innovate.  
Table 1: Classification schema for innovative healthcare technologies, with examples 
Extent of Comparative Benefit 





Negative net health benefit 
compared to existing alternatives 
Not Innovative Not Innovative 
Comparable net health benefit 
compared to existing alternatives 
Not Innovative Not Innovative 
Modest net health benefit 
compared to existing therapies 
Incremental Innovation 
(Example: dopamine agonists 
for restless legs syndrome) 
Substantial Innovation 
(Example: tissue plasminogen 
activator [t-PA] vs. streptokinase 
for acute MI) 
Significant net health benefit 
compared to existing therapies 
Substantial Innovation 
(Example: Viagra for erectile 
dysfunction) 
Radical Innovation 
(Example: sofosbuvir vs. 
interferon for Hepatitis C) 
Source: Authors’ analysis 
We consider a healthcare technology to be a consumer welfare-enhancing innovation only if it meets 
our definition of an innovation and generates consumer surplus. A product offers consumer surplus 
where consumers’ willingness to pay exceeds the transaction cost, which we consider synonymous with 
enhancing social welfare for the purposes of this study. 
While our conceptual approach to consumer welfare is consistent with the notion of consumer surplus, 
it is broader and more nuanced than the standard one-product/one-period framework. Total social 
surplus is the sum of consumer and producer surplus. Producer surplus (the difference between the 
effective price obtained by a developer and the marginal cost of producing and distributing the product) 
cannot be ignored in this case, as it is highly relevant to innovation incentives. As commonly defined, 
producer surplus will include, in addition to profits, the R&D expenditures that are used to fund 
development of future products. Maximizing consumer surplus for a new product in a given period 
leaves no room for current and future R&D. Thus, in a dynamic context, producers must appropriate 
some of the social surplus created by new products to maintain incentives to continue to innovate. 
In practice, the share of social surplus counted as producer surplus can seem low. For example, Philipson 
and Jena found that producers of HIV/AIDS drugs were able to appropriate only 5% of the social surplus 
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generated by these products.7 Expanding on this work, Philipson and Jena examined more than 200 
technologies in a cost-effectiveness registry and found that, in the case of the median technology, 
producers captured only 15% of the social surplus.8 The modeling did not account for factors such as 
public funding of R&D and the interpretation of cost-effectiveness analysis in a non-monopoly context 
that can impact whether there is under- or over-investment in R&D, so further research is needed 
before such conclusions can be reliably made. 
On a conceptual level, however, we do need to account for incentives for future innovation. Thus, we 
consider consumer surplus for a new product to be the present discounted value of the product’s 
consumer surplus for all periods over its product lifecycle, plus the present discounted value of the 
share of consumer surplus generated by all future new products whose R&D is funded in part by the 
producer surplus of the original new product. Additionally, positive social benefits can be generated by 
the introduction of a new product through effects on pricing and on the economies where R&D and 
manufacturing are conducted. In general, our notion of social welfare is dependent on the following 
factors: 
 Dynamic innovation (consumer surplus from additional new products developed with funding 
from a new product’s producer surplus); 
 General equilibrium effects on demand and pricing (consumer surplus created from competitive 
pricing within the drug class in both static and dynamic contexts [over time for the class and 
from the production of new products in newer classes]), and; 
 Economic multiplier effects from R&D, manufacturing, and distribution. 
The last effect is not unique to investment in this sector, and it may be small in relation to consumer 
surplus created by the introduction of new products. Thus, our analyses focus on the impacts that 
reimbursement methods and policies have on the introduction of new innovative products that create 
positive consumer surplus. 
  
                                                          
7
  Philipson, T.J., & Jena A.B. (2006).  Who benefits from new medical technologies?: estimates of consumer and 
producer surpluses for HIV/AIDS drugs.  Forum for Health Economics & Policy, 9(2), ISSN (Online) 1558-9544. 
8
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DEVELOPMENT OF AN ANALYTIC FRAMEWORK 
We developed a framework with which to explore the link between reimbursement and investment in 
innovations of various types (incremental, substantial, and radical), as well as products that might be 
considered to be non-innovative.9 As a first step, we reviewed academic research and policy-oriented 
publications to identify relevant models that could be adapted or adopted for this project, or that could 
inform development of a new framework. We compiled and reviewed existing models that illustrate the 
mechanisms through which reimbursement methods impact innovation, as well as models that depict 
closely-related relationships, such as the implications of reimbursement methods on R&D or on 
pharmaceutical or medical device industry profits. 
Our framework follows a conceptual model that depicts the mechanisms of influence by which various 
characteristics of reimbursement methods may affect drug and device producers’ expected return on 
investment (EROI) and other incentives to innovate. The conceptual model behind this framework 
established that, although the actual ROI measures the reward (or loss) for innovators and investors 
once a product reaches the market, an assessment of the EROI informs the decision to invest in the 
initial development of a healthcare technology. Our model uses EROI as a proxy for incentives to 
innovate, and assumes that current returns on investment are viewed as indicative of potential future 
returns. 
ANALYSIS OF KEY CHARACTERISTICS OF REIMBURSEMENT METHODS 
The project team identified key characteristics of reimbursement methods that are likely to influence 
innovation, based on theoretical underpinnings or empirical evidence. We developed an illustrative list 
of reimbursement methods or strategies in current use. Using our analytical framework, we analyzed 
which characteristics of those methods or strategies stand to impact incentives for innovation, and 
compiled the results in order to create a taxonomy of characteristics for further analysis. 
Following selection of five key reimbursement characteristics in consultation with representatives of 
ASPE, the project team conducted an in-depth review of these five characteristics to gather empirical 
evidence pertaining to the impacts of these characteristics on the level and type of innovation in 
pharmaceuticals and medical devices. The project team scanned the academic research literature using 
search engines to identify published research, government reports, white papers, and news and trade 
press included in databases such as MEDLINE/PubMed, EconLit, SCOPUS, Health Policy Reference 
Center, Pharmaceutical News Index, Google Scholar, and other databases. We identified and reviewed 
relevant books and policy reports using general Internet search engines and targeted searches of 
websites for booksellers and industry organizations.  
                                                          
9
 Bruen, B., Cohen, J., DiMasi, J., Docteur, E., Dor, A., Lopert, R., ..., Shih, C. (2014).Task 3a deliverables: conceptual 
model, recommended characteristics for analysis, and analytical framework. Interim report for the Impact of 
Reimbursement Policies and Practices on Healthcare Technology Innovation project (Department of Health 
and Human Services' Contract# HHSP23320095635) 
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EXPERT CONSULTATIONS 
The project team identified and consulted with a range of experts to complement our review of the 
research and other evidence. These experts, listed in Appendix E, included: 
• Faculty, researchers, and consultants; 
• Representatives of firms engaged in drug and device development; 
• Investors specializing in healthcare technologies, and; 
• Representatives of commercial payers, PBMs, and government agencies that pay for healthcare 
technologies. 
Consultations occurred via teleconferences and individual telephone calls. The questions for each 
session varied according to the panel’s expertise, but covered topics such as: 
• Factors that influence how developers/investors target investments to develop new healthcare 
technologies, or to find new applications for existing technologies; 
• How a product's future market environment, including reimbursement prospects and 
uncertainty, affects product development or investment decisions; 
• Which components or characteristics of reimbursement are most important in influencing how 
much and what kind of new healthcare technologies are developed; 
• How more widespread use of particular reimbursement methods in the United States might 
change product development or investment decisions; 
• Factors that influence payers’ reimbursement decisions; 
• How payers determine the reimbursement amount for a given healthcare technology; 
• Actions by payers that may foster (or inhibit) future drug and device innovation, and; 
• How reimbursement policies or practices that are emerging or becoming more widespread 
might foster or inhibit investment in consumer welfare-enhancing healthcare technologies. 
Each session was recorded and transcribed for reference by project staff. Summaries of each meeting 
were reviewed and approved by the project team and ASPE representatives. 
CASE STUDIES 
Based on our review of the literature and expert consultations, the project team identified examples of 
reimbursement methods and programs in private and public markets as candidates for case studies. 
Candidates included emerging models, as well as older methods that appeared to be gaining interest. 
ASPE representatives selected three examples for further analysis. These case studies sought to answer 
the following questions:  
• What are the objectives/rationale of the method or program?  
• What are the key characteristics of the method or program? 
• Is the approach novel or is it a variation of an already established program or method used 
elsewhere? 
• What is the stated or implied theoretical basis of the approach/method? 
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• How might broader use of the method or program influence innovation in drugs or medical 
devices? 
Using the list of characteristics of reimbursement methods with the greatest potential to impact 
incentives to innovate, and applying the framework for analyzing how reimbursement affects drug and 
device innovation that we developed, we qualitatively analyzed the potential impacts of the selected 
examples on incentives to develop innovations that improve consumer welfare. 
We examined three specific examples of reimbursement policies and practices, each identified by 
experts consulted during this project as not widely used, but worthy of closer examination to see if they 
have the potential to encourage (or discourage) future innovation: an advance market commitment, a 
value-based drug formulary, and a performance-based funding arrangement.  
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RESULTS 
Consistent with our conceptual model, the experts consulted in 
this project cited human curiosity, investment in 
science/research (public and private), and assessments of 
clinical need as important factors in fostering initial investment 
in discoveries, but there was broad agreement that 
reimbursement is a critical factor in determining which 
products reach the market. Experts noted that attractive 
candidates for investment require positive assessments of 
clinical need and anticipated reimbursement, and that 
potentially innovative products still may not make it to market 
if assessments fail to justify the continued investment to 
develop them. They noted that investors may look for products 
that offer significant improvements compared to the current 
standard of care, or are otherwise differentiated from 
technologies likely to appear in the near term, as this 
competitive advantage usually translates into more “durable” 
pricing and stronger reimbursement. 
Experts interviewed for this project noted that developers 
approach CMS, private insurers, and other payers during 
development of new products to try to understand how (or if) 
a product would be covered, and how payments would be 
structured. For drugs, discussions between payers and 
developers may occur as early as Phase II, to determine the 
endpoints of interest to payers for later trials. A popular 
guidebook for device developers puts “payer advocacy” 
approximately one year prior to expected launch and 
“conduct[ing] payer education” roughly eight months prior to 
launch. However, the authors note that timelines vary 
considerably depending on the type of device, whether it fits 
under an existing reimbursement code or needs a new one, 
and other factors.10 
The experts we interviewed also suggested that 
reimbursement is growing in importance as the unit costs of 
new products exceed the point where third-party coverage is 
                                                          
10
 Yock, P., Zenios, S. A., & Brinton, T. J. (2015). Biodesign: the process of innovating medical technologies. 2nd 
Edition. Cambridge University Press. 
Quotes from experts 
My general experience is that 
when organizations invest in early 
discovery, it’s mostly driven by 
science… after the product gets 
further along in its development 
life cycle and larger and larger 
investments are needed, that’s 
when people start thinking more 
about the clinical utility… the value 
in the marketplace… will physicians 
want to prescribe it… will payers 
want to pay for it? But there is a 
trend… in general to move that 
marketplace insight earlier in the 
development process. 
[At the last few places I have 
worked, investment is] primarily 
driven initially by the clinical 
need… You are trying to solve that 
problem up front... and then the 
second question usually resolves 
around the business side… the 
regulatory path, the 
reimbursement, the market size. 
We have a very formal process that 
we begin very early in product 
development life cycle, and we 
have our reimbursement staff 
across the company very involved 
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essential for individual affordability. The broad availability of reimbursement through insurance likely 
contributes to higher costs for healthcare technologies. New products need reimbursement, but 
reimbursement leads to new products, which creates the need for more reimbursement. 
Reimbursement also decreases cost sensitivity for consumers, so manufacturers can charge higher 
prices. 
TRACING THE LINK FROM REIMBURSEMENT TO INNOVATION  
The analytical framework that we developed for this project describes a way in which the (prospective) 
impact on innovation from a particular reimbursement method or strategy can be assessed, in 
qualitative (direction and relative magnitude of impact), if not quantitative terms. This framework, 
shown in Figure 2, posits that reimbursement policies and practices can affect product developers’ ROI 
directly in three ways. The first is by establishing a particular payment level, which in turn affects 
average sales price in line with the share of the prospective market represented by the payer. The 
second is by setting a volume of sales at that payment level, as may occur in the case of competitive 
bidding, for example. The third is by influencing seller costs associated with development, manufacture, 
or sale of a healthcare technology. 
Figure 2: Framework for assessing effects on innovation 
 
Source: authors’ analysis 
Reimbursement policies also indirectly influence ROI by establishing different incentives for key actors, 
including patients/consumers, dispensers, providers, sellers, and payers. In turn, these incentives affect 
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While researchers have investigated the links between EROI, ROI, and pharmaceutical industry R&D 
(see, for example, Scherer11), we found no empirical evidence that directly connects ROI with the 
quantity or quality of healthcare technology innovation. In general, we assume that larger expected 
returns on investment provide more incentives to invest in development of novel healthcare 
technologies. We also assume that expectations and time horizons tend to differ between large, 
established manufacturers and relatively small biotechnology firms and start-ups. The latter have 
shorter-term horizons; the former have longer-term horizons. Innovators’ and investors’ expectations 
and time horizons also vary by therapeutic class. These differences make it very difficult to draw general 
conclusions about the link(s) between ROI and innovative products. The dashed lines between ROI, 
investment in R&D, and the various categories of innovation illustrate this uncertainty.  
We add a second level of assessment that separates each of the novel products into two groups: those 
that enhance consumer welfare and those that do not. As noted earlier, we use consumer surplus – the 
amount by which consumers’ willingness to pay exceeds the transaction cost – as the measure of 
consumer welfare. We do not depict this assessment visually in Figure 2, but it essentially cuts each 
category of novel products into two parts. For example, a non-innovative product may still enhance 
consumer welfare by achieving comparable effects at lower cost, and an otherwise-innovative product 
may fail to enhance consumer welfare if the opportunity costs of its acquisition and diffusion exceed the 
value of the attained benefits. Similarly, a developer may view as innovative a pacemaker that offers 
thousands of sophisticated monitoring options, but a payer may view the added complexity as 
producing uncertainty or risks that may outweigh the benefits of the innovation, because individual 
physicians can only understand a fraction of the options.  
KEY CHARACTERISTICS OF REIMBURSEMENT METHODS 
Different characteristics of reimbursement policies and practices serve to define payment levels, volume 
of service, and seller costs. They also establish different incentives for key actors, which indirectly 
influence these determinants of ROI. We selected five characteristics of reimbursement policies and 
practices that appear to be important in explaining the impact of reimbursement policies and practices 
in motivating and directing innovators’ efforts (Table 2). 
  
                                                          
11
 Scherer, F. M. (2001). The link between gross profitability and pharmaceutical R&D spending. Health Affairs, 
20(5), 216-220. doi:10.1377/hlthaff.20.5.216 
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How payers make decisions on which drugs, devices, and other 
healthcare technologies to make available, at what cost, and for whom. 
Product categorization and 
differentiation 
How payers distinguish the drugs or devices that they cover.  
Method of payment The terms under which a payer makes reimbursement to a provider. 
Method of defining the 
payment amount 
The methods used to establish the amount the third-party payer will 
reimburse a provider or supplier furnishing a healthcare technology to a 
patient. 
Patient cost sharing Out-of-pocket costs borne by consumers, net of insurance coverage, 
when they obtain services or purchase prescription drugs, durable 
medical equipment (DME), or other health technologies 
Source: authors’ analysis 
For most U.S. payers, the REIMBURSEMENT DECISION-MAKING PROCESS involves pharmacy and 
therapeutics (P&T) committees or other authorized decision-makers who are responsible for evaluating 
drugs and devices translating the available evidence into decisions for prescribing, availability, and 
reimbursement of drugs and devices. These decision-makers follow a sequential series of steps, as 
outlined in Appendix A.12 Groups of providers, including specialists in the disease, procedure, and/or 
patient population for which the technology is intended, may evaluate devices used solely in medical 
practice (i.e., not by patients at home). Payers use these evaluations to make decisions on what 
products to include in formularies, at what price, and for whom. The decision-making process also 
encompasses decisions about which tools to use to attempt to affect provider choices/prescribing and 
manage utilization, such as formulary tier placement (which may affect patient cost sharing), prior 
authorization, step therapy, and quantity limits. As such, the decision-making process links the four 
other characteristics noted below. 
Payers use a variety of approaches to PRODUCT CATEGORIZATION AND DIFFERENTIATION in the 
course of deploying their reimbursement practices and policies. They can distinguish between drugs or 
devices in terms of patent status, route of administration, care setting, price, value, or other attributes. 
Administrative approaches, which may be undertaken without reference to value or evidence, include 
the following: 
1. Pharmacy versus medical benefit: All payers make an administrative distinction between drugs 
or devices subsumed under the pharmacy versus medical benefit. Almost all devices and 
physician-administered drugs are considered part of a payer’s medical benefit; self-administered 
or outpatient drugs are categorized under the pharmacy benefit.  
 
                                                          
12
 Wang, Z., Salmon, J.W., & Walton, S. (2004). Cost-effectiveness analysis and the formulary decision-making 
process. Journal of Managed Care Pharmacy, 10(1):48-59. 
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2. Substitution: Payers use different approaches to encourage generic substitution as a cost-
containment measure. Over 80% of prescriptions dispensed in the United States are for 
generics, and much of this is due to payers driving substitution of generic for originator 
prescriptions.13 Generic drugs enhance consumer welfare when offered at prices below the 
maximum price consumers would be willing to pay. 
 
3. Rebate mechanism: Almost all payers and manufacturers negotiate rebates in exchange for 
increased market share; a manufacturer of a particular drug rebates a certain amount to the 
payer if the payer successfully increases sales of the drug. Payers influence market share by 
granting a drug preferred status on the formulary. Preferred drugs are in lower patient cost-
sharing tiers, while non-preferred drugs are in higher cost-sharing tiers. More competitors in a 
therapeutic class allows for larger rebates, as competition among products increases payer 
leverage. 
Value-based approaches include product exclusions; value based-insurance design; coverage with 
evidence development; risk-sharing agreements; and other methods based on evidence or value. 
1. Excluded products: A few PBMs have removed certain brand products with clinically equivalent 
alternatives from the formulary entirely.  One purpose of exclusions is to extract greater price 
discounts and rebates. When a payer or PBM delists a drug or device, it rewards the 
manufacturers of competing products with an increase in market share. Exclusions also cancel 
out the value of manufacturers’ discount cards/coupons from cost-sharing offset programs. 
 
2. Value-based insurance design (VBID): A 2010 review estimated that about one-third of payers 
have adopted value-based insurance design, wherein they have reduced cost-sharing for a 
number of “high-value” products and/or services in highly prevalent disease categories and 
raised cost-sharing for certain “low-value” products and/or services.  However, it is not always 
clear what is “value-based,” most adopters only use this design for a very limited number of 
therapeutic classes, and this still leaves a majority of payers (at least in 2010) who do not use 
value-based insurance design at all. Value-based formularies, a form of VBID, differentiate 
groups of drugs based on the disease or condition treated and the therapeutic effect of 
treatment. We discuss one example, a value-based formulary pilot program run by Premera 
Blue Cross, later in this report and in Appendix C. 
 
3. Coverage with evidence development: Coverage with evidence development (CED) involves 
coverage of a drug or device with the stipulation that payers and manufacturers collect post-
marketing data on the drug or device’s real-world safety and effectiveness. Given the possibility 
of lags between marketing authorization and payer decisions to reimburse, as well as significant 
uncertainty at launch, payers may be able to foster innovation by shifting more of the clinical 
                                                          
13
 Kleinrock M. (2012). The use of medicines in the United States: Review of 2011. IMS Institute for Healthcare 
Informatics. Parsippany, New Jersey. 
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evidence gathering to the post-marketing space while providing patients with access to the 
products being evaluated.  To continue to have market access, manufacturers will have to 
demonstrate that their products confer added benefits. 
 
4. Risk-sharing arrangements: Related to CED, “risk-sharing arrangements” (RSAs) between payers 
and manufacturers have grown in number internationally, although there are more publicized 
examples overseas than in the U.S.  RSAs typically involve measurement of the performance of 
a technology in a defined patient population over a specified period. They may tie 
reimbursement for covered products to the measure of clinical outcomes; condition 
continuation of coverage of a product on meeting specified responses to treatment or absence 
of disease progression; or tie reimbursement to financial or utilization outcomes. 
 
There has been limited experience to date in performance-based risk sharing both in the U.S. 
and other countries. Challenges to broader implementation include high transaction costs; lack 
of acceptable (e.g., valid, objective) outcome metrics; difficulties in determining treatment 
effects; and the absence of suitable data capture systems. We examine these issues in the 
context of a performance-based RSA for Velcade in the United Kingdom later in this report and 
in Appendix D. Nearly all RSAs have been for drugs, but there was a well-documented United 
HealthCare (UHC)/Genomic Heath (GH) performance-based RSA for the Oncotype DX diagnostic 
that began in 2007, and other agreements involving diagnostics/devices have emerged in more 
recent years.  
In the United States, there is currently more use of administrative than value-based approaches. 
In the United States, different METHODS OF PAYMENT are employed for drugs and devices used in the 
care of hospital inpatients; physician-administered drugs and medical devices used in ambulatory care 
settings; and prescription medicines and medical products prescribed for home use. The same payer 
may use different payment methods for different plans (e.g., health maintenance organization [HMO], 
preferred provider organization [PPO], point-of-service [POS]), and employers and other plan sponsors 
may influence the payment method selected for a particular plan. Different payers also make different 
reimbursement decisions, even when employing similar methods. The result is a complex system of 
reimbursement involving many decision-makers and resulting in substantial variation among payers. 
While methods vary, there is a fundamental distinction between whether payers compensate providers 
or suppliers of healthcare technologies on a per-unit basis or as part of a bundled payment for a package 
of goods and services used for a clinically-defined episode of care.14  
 In the case of prescription medicines and durable medical equipment (DME) used in the home 
setting, per-unit payments are the norm; distinctions lie primarily in how per-unit payment 
                                                          
14
 Both per-unit and bundled payments may be, and increasingly are, subject to retrospective adjustments, 
withholds and/or bonuses based on meeting of performance targets (so-called pay for performance). 
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amounts are determined. For DME prescribed for home use, payers are increasingly using 
competitive bidding for products judged therapeutically equivalent, while other products are 
reimbursed according to a fee schedule. 
 Payers in the United States use bundled payments primarily for care associated with inpatient 
and outpatient hospital treatment, although some are experimenting with bundled payments 
for care provided in physicians’ offices and clinics.15 
 In general, bundled payments cover drugs provided in hospitals, and the hospital is not 
permitted to bill the payer separately unless the drug exceeds a defined threshold cost. 
Exceptions are often made for products designated as highly innovative and/or high cost, with 
the result that default unit pricing is applied for those products. 
 Similar to drugs, devices and diagnostics used in inpatient and outpatient hospital care are 
usually bundled, with exceptions for products subject to pass-through payments. Medicare is 
working to expand the use of bundled payments for devices used in outpatient and ambulatory 
care settings.16 
 Drugs administered by physicians in offices or clinics usually are paid on a per-unit basis. 
 As a rule, payers compensate pharmacies for each unit sold; however, specific payment levels 
are negotiated with the pharmacies, and additional rebates or discounts may be negotiated 
directly with the product manufacturers, such as part of a determination of formulary tier 
placement.17 
The use of similar payment methods in many areas by different payers likely reflects the influence of 
Medicare, which is the largest single payer in the United States, and forged the path in developing 
technical approaches and tools employed in payment methods. The up-front costs associated with 
developing new methods can be significant, and private payers would likely face barriers to both 
investment and deployment of novel methods.  
Public and private payers use different guidelines and metrics to DEFINE THE PAYMENT AMOUNT 
they will reimburse a provider or supplier furnishing a healthcare technology to a patient.18,19  In the 
                                                          
15
 For example, Medicare tested bundled payments in the outpatient setting in the Medicare Cataract Alternative 
Payment Demonstration. For further information, see: Painter, M. W., Burns, M.E., & Bailit, M.H. (2012, January). 
Bundled payment across the U.S. today:  Status of implementation and operational findings. Health Care Incentives 
Improvement Institute Issue Brief. 
16
 Change is also under way on the ambulatory care front, where a move toward a more comprehensive approach 
to reimbursement is being discussed because of concerns raised by medical device policy experts about code 
stacking, a practice in which the payment for a diagnostic test is determined by adding up the costs of the 
individual component steps. 
17
 Formularies are lists of reimbursable drugs or devices, which include provisions for patient cost-sharing as well 
as coverage conditions. Formulary development is normally informed, in part, by evidence on the safety, 
effectiveness, and/or cost of drugs and devices. 
18
 In the interests of clarity, we exclusively use the term “amount” to refer to how much a payer pays a provider for 
a healthcare technology. Other terms in common use include payment rate and payment level. 
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case of bundled payment, payers seek to approximate the cost of drugs and devices used when defining 
the bundled payment amount. Technological innovations are accounted for either through updates of 
the bundle or pass-through payments, in the case of technologies considered to be highly innovative, 
highly costly or both. When payers are reimbursing on a per-unit basis, there are four basic approaches: 
 External benchmarking, or defining a payment level based on the sales price in the market or 
markets in which the product is sold, or an estimate of the provider's acquisition cost; 
 Internal benchmarking, or defining a payment level based on what is paid for comparable, 
covered products for which the payer has already established a payment amount;  
 Value-based payment, or defining a payment level based on an assessment of the product's 
value, such as benefits to the patient, to the payer, or to society as a whole, including cost 
savings associated with use of the product in place of a therapeutic alternative, and; 
 Lowest possible price payment, or defining a payment level based on the lowest price that the 
seller will accept. 
External benchmarking is the most widespread approach in prescription drug pricing for publicly 
financed health programs in the United States and most health systems in the developed world. For 
example, most public programs in the U.S. benchmark payment levels for prescription drugs using 
published prices from commercial vendors (e.g., average wholesale price [AWP]) or reported sales prices 
between manufacturers and purchasers (e.g., average sales price [ASP] or pharmacy invoices). Because 
Medicare publishes codes and payment rates, its payment levels are visible benchmarks and may 
influence some payment decisions by other payers.20,21 Nevertheless, Medicare’s method of setting 
payment levels for diagnostics, based on the average wholesale cost of the steps involved plus a mark-
up, is often criticized as being outdated, subject to gaming by laboratories, and not reflective of the 
products’ underlying health benefits.22,23 Medicaid’s drug payment formulas are similarly criticized.24  
                                                                                                                                                                                           
19
 This discussion focuses on the manner in which the initial payment amount is defined; a secondary question (not 
addressed here) concerns how the payment amount is updated to reflect new evidence, changes in technology or 
practice patterns, or other factors. 
20
 White, C. (2013). Contrary to cost-shift theory, lower Medicare hospital payment rates for inpatient care lead to 
lower private payment rates. Health Affairs, 32(5):935-943. 
21
 Clemens, J., & Gottlieb, J. D. (2013, October). In the shadow of a giant: Medicare’s influence on private physician 
payments. NBER Working Paper No. 19503. Cambridge, MA: National Bureau of Economic Research. 
22
 Carlson, B. (2010). Seeking a coding solution for molecular tests: managing the estimated 1,700 molecular tests 
now on the market is impossible without a unique CPT code for each test. What’s at stake? The future of 
personalized medicine. Biotechnology Healthcare, 7(4), 16–20. 
23
 Gass Kandilov, A. M., Pope, G. C., Kautter, J., & Healy, D. (2012). The national market for Medicare clinical 
laboratory testing: implications for payment reform. Medicare & Medicaid Research Review, 2(2), 
mmrr.002.02.a04. http://doi.org/10.5600/mmrr.002.02.a04 
24
 U.S. Department of Health and Human Services’ Office of Inspector General. (2011). Review of drug costs to 
pharmacies and their relation to benchmark prices. A-06-11-00002. 
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Reimbursement methods and payment rates used by private payers are usually proprietary and 
confidential. The methods used to compensate pharmacies for drugs provided under the pharmacy 
benefit programs of private payers in the United States, including Medicare Advantage Plans, most 
Medicaid managed care plans, and Medicare Part D standalone drug plans, are largely unknown because 
payers retain proprietary interest in their payment formulas.25 Only limited details, such as average 
discounts from AWP based on small samples of employer-based plans, are publicly available.26 Private 
payers typically negotiate payment terms directly with hospitals, physicians, and other providers.27 
Because competitive pressures motivate private health plans to minimize costs, it is likely that many 
private payers employ the lowest possible price approach, in which their payment amount is 
determined by the degree of leverage they have in a market transaction when facing a particular seller 
of a healthcare technology.28  
A relatively smaller number of payers, such as insurers in Germany, the Netherlands, and the Czech 
Republic, employ a form of internal benchmarking (commonly referred to as “reference pricing” or 
“therapeutic reference pricing”) to define the maximum price they are willing to pay for a product that is 
a) determined to be comparable to others, and b) where the payer has pre-established a payment 
amount.29 Other payers, such as the national health services of the United Kingdom and of Sweden, are 
experimenting with value-based payment.30 
Though internal benchmarking is seldom used in the United States, one notable exception is Medicare’s 
functional equivalence and least costly alternative policies. In the early 2000s, Medicare enacted policies 
for a limited number of drugs and devices where the program would only pay the cost of the least costly 
drug or device in the case of two or more drugs or devices that were deemed functionally or 
therapeutically equivalent. A high-profile example was CMS’ decision to reduce the payment rate for 
darbepoetin alfa (Aranesp) by considering it functionally equivalent to epoetin alfa (Procrit).31  The 
                                                          
25
 Academy of Managed Care Pharmacy. (2013). AMCP guide to pharmaceutical payment methods, Version 3.0, 
executive summary. 
26
 Pharmacy Benefit Management Institute. (2013). 2013-2014 Prescription drug benefit cost and plan design 
report. 
27
 Sorenson, C., Drummond, M., & Burns, L. R. (2013). Evolving reimbursement and pricing policies for devices in 
Europe and the United States should encourage greater value. Health Affairs, 32(4):788-796. 
28
 The use of this approach was discussed by experts representing payers who were consulted as part of the 
research for this project. One expert opined that neither external price benchmarking nor leverage-based pricing 
offered ideal outcomes, but that appetite for moving to value-based payment was not yet primed in the U.S. 
context. 
29
 This approach is also used by Canada’s Patented Medicine Pricing and Review Board, which sets nationally 
binding price caps for patented medicines sold in Canada. Canadian payers (private plans and provincially-
administered public programs) use different approaches to define reimbursement payment levels. 
30
 Paris, V. & Belloni, A. (2013). Value in Pharmaceutical Pricing. OECD Health Working Paper no. 63. Paris: OECD. 
31
 Rubinstein E. (2006). Application of `functional equivalence’ to payment for office-administered 
biopharmaceuticals. Biotechnol Healthc;3(6):64-65. 
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Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) prohibited use of this 
standard for other drugs, and CMS stopped applying it to Aranesp and Procrit in 2006.32  In 2008, the 
U.S. District Court of the District of Columbia held in the case of Hays v. Leavitt that the least costly 
alternative policy for another drug, DuoNeb (albuterol and ipratropium bromide), was not authorized 
under Medicare’s statute.33 After the U.S. Court of Appeals for the District of Columbia Circuit upheld 
the District Court’s decision, CMS instructed contractors to suspend and remove all least-costly 
alternative provisions.34  
PATIENT COST SHARING refers to out-of-pocket costs borne by consumers, net of insurance coverage, 
when they obtain services or purchase prescription drugs, durable medical equipment (DME), or other 
health technologies. A cost-sharing approach generally consists of two main elements: The cost-sharing 
“method” refers to deductibles, fixed copayments, and variable coinsurance.35 The “level” of cost 
sharing refers to the overall amount contributed by the beneficiary, such as high deductibles versus low 
deductibles, or high copayment rates versus low copayment rates. Tiered cost sharing, which is closely 
linked to the payer’s categorization or differentiation, adds an additional dimension. 
There is substantial variation in cost sharing among different payers and plan offerings. Commercial 
plans typically use a mix of deductibles, copayments, and/or coinsurance for medical services, DME, and 
other devices. Deductibles and coinsurance are the main cost-sharing methods in Medicare’s Part A 
(Hospital Insurance) and Part B (Medical Insurance).36 There is no annual limit on an individual’s cost-
sharing liability. Fixed copayments are much more common in Part C (Medicare Advantage; managed 
care) and Part D (stand-alone Medicare prescription drug plans [PDPs]), which private carriers operate.37 
Under Medicaid, states may require patient cost-sharing for many covered services, but the level is 
generally limited to “nominal” fixed copayments; a beneficiary’s total annual cost-sharing is limited to a 
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modest percentage of family income; and federal law prohibits cost-sharing for several categories of 
Medicaid beneficiaries and certain services.38 Most state Medicaid plans require cost sharing for 
prescription drugs and DME.39 
For prescription drugs, most commercial plans use tiered cost sharing with increasing levels on higher 
tiers; fixed copayments are much more common than percentage coinsurance in these plans.40,41 Drug-
benefit specific deductibles, out-of-pocket limits, or maximum annual benefit limits for drugs are 
relatively rare in commercial plans.41 In 2015, roughly 60% of Medicare Part D drug plans have a 
deductible and nearly all have five cost-sharing tiers: two for generics (preferred/non-preferred), two for 
brands (preferred/non-preferred), and one for specialty drugs.42 Although Part D plans use copayments 
for most tiers, they are increasingly using coinsurance for non-preferred and specialty drugs. 
Variations in cost-sharing approaches within the United States, and throughout the world, reflect the 
diversity of payers. Within the U.S., national, regional (State) and local governments; employers; labor 
unions; and other organizations make important decisions about the levels and methods of cost-sharing 
in plans that they either operate directly (self-insured plans) or purchase from insurance companies 
(fully-insured plans) for their employees, members, citizens, or constituents. Purchasers may have less 
direct influence over the designs of fully-insured plans offered by commercial carriers, which frequently 
offer a pre-determined menu of coverage options from which group purchasers select. Commercial 
carriers also design plans for non-group markets, such as the insurance exchanges established by virtue 
of the Affordable Care Act. All public and private insurance plans in the U.S. also operate within a web of 
federal and state government laws and regulations that may influence the range of acceptable cost-
sharing levels. 
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HOW REIMBURSEMENT CHARACTERISTICS AFFECT COMPONENTS OF ROI AND INCENTIVES 
TO INNOVATE  
As outlined in the analytic framework (Figure 2, above), reimbursement stands to affect the ROIs for 
healthcare technologies, and EROIs for products in development, by influencing sales prices, sales 
volumes, and sellers’ costs of development, manufacturing, and sale of these products. Prospective 
innovators take into account expectations regarding the impact of current and expected future 
reimbursement policies and practices when deciding to invest in R&D and directing investments to 
particular therapeutic classes.43 They have greater incentives to invest in the types of innovations that 
they expect will produce larger rewards; typically the desired rewards are monetary (i.e., ROI), although 
some developers and investors may also attach importance to non-monetary rewards (e.g., discovering 
a cure). Whether and how reimbursement occurs for a product influences its effective price and volume 
of sales. These factors, in turn, determine the revenues and profits for the product, which are important 
determinants of the ROI for its innovator and investors. A positive ROI rewards successful innovators 
and will, in theory, spur the next generation of investment. 
Drawing on economic theory, review of literature, and expert consultation, this analysis examined the 
reimbursement policies and practices described in the previous section, and assessed the direction and 
general magnitude of their effects on drug and device use and innovation. The findings suggest a 
number of ways in which characteristics of reimbursement policies and practices can align technology 
producers’ returns with the societal value of the innovations they produce. We discuss the effects of 
each reimbursement policy and practice separately, below. 
THE REIMBURSEMENT DECISION-MAKING PROCESS 
Many outcomes of the reimbursement decision-making process have direct implications for sales prices 
(through payment, rebates), sales volume (through approval or rejection, drug and device-use 
conditions), and total costs to developers (through requirements for data for clinical and cost 
effectiveness evaluations). Approaches used in making reimbursement decisions also impact patients 
and care providers through availability of particular products, as well as payment and cost sharing for 
drugs and devices, potentially leading to indirect effects on sales volume. 
The U.S. retains a pluralist framework with respect to reimbursement decision-making. There are no 
centralized pricing and reimbursement decisions; instead, hundreds of payers use their own assessment 
approaches to reach their judgments. Although payers in the United States generally go through a 
similar set of steps in the decision-making process (see Appendix A), differences in implementation lead 
to many variations in the interpretation of evidence of clinical and cost-effectiveness for particular 
products, and ultimately to the decisions on coverage and conditions of reimbursement. Variability in 
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decisions may be appropriate, given that different employers, payers, and consumers may have 
different preferences and objectives. At the same time, decentralization weakens the effect of decisions 
made by all but the largest payers, in terms of ability to motivate developers. Experts consulted during 
this project agreed, noting that although payers individually send signals about where developers should 
invest, those signals are not coordinated and are not necessarily strong. There also may be a lag 
between the signal and the industry response. Lags may be due to lack of scientific opportunity, which 
contribute to waves of innovation when scientific breakthroughs occur, but may also occur when there 
is significant uncertainty about how a new product would be reimbursed. 
Payers also have varying levels of accountability and transparency. Public payers, namely those serving 
beneficiaries in the non-commercial market, such as Medicare, Medicaid, Veterans Affairs, and Indian 
Health Service, are generally expected to be more accountable and transparent than private payers. In 
this respect, payers tend to reveal the general contours of their decision-making processes, though not 
the specifics. For example, rebates are proprietary, so the public has no way of knowing their 
magnitude. Payers have generally been hesitant to shed light on the actual evidence base and decision-
making process underlying their reimbursement decisions, so current formulary decision-making is 
mostly a “black box.”44 Even when researchers attempt to pry it open, there are often unique factors 
that influence each particular coverage decision. Hence, knowing the precise weights attached to factors 
that figure in reimbursement decisions is difficult, if not impossible. This implies that developers must 
anticipate different questions of value, depending on which payer (or set of payers) they are most 
concerned with. It also means that there are less traceable and unambiguous assessments of the 
direction or magnitude of effects attributable to the decision-making process itself, compared to specific 
features discussed later in this section, such as product categorization, payment, and cost sharing. 
During the clinical and/or economic evaluation phases, there may be disconnects between the amount 
of evidence payers desire and what is available at the time decisions are made. Payers generally prefer 
to review evidence from randomized clinical trials (RCTs) and other comparative effectiveness research 
(CER) studies when assessing clinical and cost-effectiveness.45 Studies have noted that available data are 
often inadequate or irrelevant to inform decision-making, due to the scarcity of relevant head-to-head 
comparisons, a perceived lack of credibility with manufacturer-funded studies, and a paucity of available 
economic information.46, 47 Comparative economic evidence is often generated post-launch in non-
randomized studies; therefore payers often seek other kinds of study designs, including retrospective 
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 Dean, B.B., Ko, K.J., Graff, J.S., Localio, A.R., Wade, R., & Dubois, R.W. (2013). Transparency in evidence 
evaluation and formulary decision-making. P&T, 38(8):465-483. 
45
 Wang, Z., Salmon, J.W., & Walton, S. (2004). Cost-effectiveness analysis and the formulary decision-making 
process. Journal of Managed Care Pharmacy, 10(1):48-59. 
46
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claims analyses to get needed information.48 Industry experts and investors interviewed for this project 
noted that manufacturers are beginning to anticipate payer data requirements before they start phase 
III studies. 
Payers also differ in the ways they approach the establishment of drug and device use conditions. In 
certain instances, payers may not be able to employ the full array of utilization management tools, 
including pricing and patient cost-sharing, due to limited treatment options, such as cases involving 
orphan diseases, or owing to the sensitive nature of the disease, including life-threatening conditions 
such as cancer or HIV/AIDS. Regulations may prohibit use of certain utilization management tools, such 
as coverage limits and patient cost-sharing. In these instances, payers have less pricing leverage and may 
be forced to manage pharmaceutical and device use through instruments such as prior authorization 
and step therapy.  
Ideally, there would be a correlation between preferred formulary placement (with lower patient cost 
sharing) and greater cost-effectiveness, fewer safety concerns, and/or greater certainty around 
evidence.49 However, evidence is mixed on the existence of an association between these factors and 
preferred formulary placement. Furthermore, it is questionable whether cost-sharing tier placements 
within formularies actually represent, on balance, evidence-based lists of products that reflect their 
benefits, relative to costs.47 This suggests that evidence is either not being gathered, or if it is, it is not 
always being applied in such a way that formularies reflect added value. 50,51,52 If a reimbursement 
process rewards non-innovative products with a high ROI, this result muddles incentives for payers to 
pursue more innovative products.  
DESIGNING DECISION-MAKING PROCESSES TO FOSTER INNOVATION 
Approaches to reimbursement decision-making force developers to anticipate questions of value in the 
clinical development pipeline, not simply at or near the point of launch. Industry and investor experts 
consulted for this study noted that there is a trend to start reimbursement assessments earlier in the 
development process, mostly during Phase II and Phase III, although approaches vary among and within 
industries. For example, one expert noted that some companies will not focus scientific research in 
areas that do not fit within an existing code for reimbursement. Another noted that some companies 
conduct formal reimbursement assessments very early in the product development life cycle. A third 
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panelist noted that some companies, especially small ones, lack the expertise or resources to conduct 
thorough market assessments. Discussions between developers and payers are usually proprietary, 
although publicly available information indicates that payers and manufacturers discuss endpoints of 
importance to the value assessment of a drug or other technology. The discussion among the experts on 
our panels implied that device developers account for reimbursement earlier in the process than drug 
developers, but this impression may be due to the (usually) shorter timeline for development of devices. 
The discernible impact on incentives to innovate can be substantially affected by the manner in which 
different reimbursement decision-making processes (by different payers) are transparent, evidence-
based, consistent, and timely. 53, 54  Theoretically, it might be expected that transparency in decision-
making would lead to a more competitive marketplace and fewer market distortions, which in turn 
would lead to lower prices for products with less added value, and higher prices for those with more 
added value. Patients, providers, policymakers, and manufacturers would benefit from having 
information on how different formulary decisions are made, not merely what is on the formulary. 
Knowing the kind of evidence used to inform formulary decisions could increase clarity with respect to 
which factors are influential; consistency in understanding how other payers handle comparable 
situations; and transparency by ensuring those involved in the decision-making process understand 
what was decided and why. 
An evidence-based process means that the rationale for decisions reflects relevant data on safety, 
efficacy, cost-effectiveness, and budget impact. In theory, decisions that favor novel products aimed at 
unmet needs, and which provide net benefits relative to existing therapies, should enhance consumer 
welfare. Reimbursement decisions that fail to reflect the relative added value of a product will be 
ineffective in establishing incentives for innovations that enhance consumer welfare. If payers do not 
assess cost-effectiveness and take default “yes” decisions when data are absent, they are likely to be 
creating incentives to overinvest in R&D. Ideally, lower expected ROIs for products that do not add 
significant value would lead to less R&D spending on products deemed to be of less value, or that do not 
address an unmet need. 
Expanding data requirements for reimbursement decision-making, before and after product launch, are 
a clear signal to developers of payers’ growing emphasis on better aligning their coverage and payment 
decisions with outcomes and value. They also directly influence the total costs of development of new 
products, to the extent that developers must conduct additional studies. Increased data requirements 
carry some uncertainty for developers, to the extent that negative results may lead to less favorable 
reimbursement decisions. Positive results, on the other hand, should improve a developer’s 
reimbursement prospects. 
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It is unclear whether the drug development paradigm is changing in 
response to increased evidence demands from payers, government 
policymakers, and consumers. Anecdotal evidence suggests changes 
may be under way, including the inclusion of active comparators in 
clinical trials, involvement of stakeholders (e.g., patient 
representatives, payers, and providers) to help define key Phase IIb 
and III study design features, incorporation of patient-centered 
outcome measures, and earlier planning for Phase IV studies. 
However, we do not have firm evidence that this is indeed 
happening. 
Consistency in decision-making is desirable, although variation is to 
be expected given the multitude of different payers. Patient access 
may vary from one payer to another for the same drug or indication, 
with the result that mixed signals are conveyed to manufacturers 
regarding the relative value of their product to buyers. Transparency 
and evidence-based rationales can help to explain these differences 
and may encourage greater consistency, where appropriate. 
Developers and investors have a dim view of uncertainty brought 
about by an opaque decision-making process; they also want to 
minimize delays in decision making between marketing 
authorization and formulary placement, which shorten the effective 
time in which a product has market exclusivity and can garner a 
higher price and larger market share.55 We examined one approach 
that can reduce uncertainty for developers, an advance market 
commitment, in our case studies (Box 1). 
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less investment.  
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Table 3: How the design of a reimbursement decision-making process may affect the marketplace and 
innovation 
Approach 
Impacts on Patients & 
Providers 
Impact on Sellers 
(Manufacturers) Impact on Innovation 
Transparent More understanding of the 
factors that drive 
decisions. 
More understanding of the 
factors that drive decisions, 
and the types and amount of 
evidence required.  
Potential effects on sales 
prices if confidential 
discounts/rebates are 
exposed. 
In theory, sends clearer signals 
to developers and investors 
about the types of products 
that payers (and patients) 
value. To the extent that 
payers value innovations, this 
should encourage more R&D 
targeted at those types of 
products. 
Evidence-based More understanding of the 
evidence in favor of, or 
against, use of a particular 
product. 
Could increase costs of 
development, if more or 
larger studies are required. 
May add some uncertainty 
due to the potential for 
negative results from 
additional studies, but sellers 
may gain pricing power if 
results are positive. 
In theory, lower expected 
ROIs for products that do not 
add significant value would 
lead to less R&D spending on 
products deemed to be of less 
value, or that do not address 
an unmet need. 
Consistent Patients and providers 
may prefer consistency – 
rather than unexplained 
variation – across the 
various formularies that 
they are faced with.
56
 
Less uncertainty in models of 
expected ROI for new 
products. 
Unlikely to have a differential 
effect on R&D spending aimed 
at innovative vs. non-
innovative products. 
Timely More timely processes 
bring new treatments to 
patients and providers 
more quickly. 
More timely processes get 
new products in use more 
quickly (in the case of 
positive decisions), or leave 
more time during the market 
exclusivity period for the 
developer to get more 
favorable placement (in the 
case of negative decisions). 
Unlikely to have a differential 
effect on R&D spending aimed 
at innovative vs. non-
innovative products. 
Source: authors’ analysis 
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BOX 1 | HI HEALTHINNOVATIONS: AN EXAMPLE OF REDUCING UNCERTAINTY WITH 
ADVANCE MARKET COMMITMENTS 
Uncertainty is a driving force behind product development and investment decisions; experts 
consulted for this project agreed that a greater perceived risk is likely to be a disincentive for 
investment. One method of reducing uncertainty for developers is an advance market 
commitment, an agreement between the product developer(s) and potential purchaser(s) that 
effectively guarantees a market for a proposed product. Although it initially took root in vaccine 
development, the basic concept is applicable to other circumstances, in which a payer or group 
of payers seeks to encourage development of a new product that the market does not currently 
offer through direct investment or some form of prize for successful development. 
Believing that meeting an unmet need for hearing aids would produce happier customers, 
health benefits, and potentially lower health care costs, UnitedHealth Group invested directly in 
a product and distribution model meant to fill that gap. hi HealthInnovations, an Optum 
business and UnitedHealth Group company, worked with a manufacturing partner to develop 
and produce hearing aids with a specific set of characteristics, at a price low enough to attract 
subscribers and to make the overall cost affordable to the payer and to consumers. Initially, hi 
HealthInnovations offered the hearing aids directly to the public and to people enrolled in 
UnitedHealthcare’s Medicare Advantage and Part D plans, and later expanded to 
UnitedHealthcare’s commercial and vision plans, as well as through programs directly to 
employers and other health plans. Although we could not obtain evidence to directly measure 
the success of the hi HealthInnovations program, it appears to have met its goals of filling an 
unmet need for hearing aids by bringing to market advanced hearing aids at lower prices, and 
improving access to hearing care.  
Based on the definition of innovation used in this project, the hearing aids offered by hi 
HealthInnovations might best be deemed incremental innovations. The advance market 
commitment and new distribution model, rather than the devices, may be the greater 
innovations, which helped to make hearing aids more affordable and accessible. The specific 
approach in this case seems most appropriate for similar instances where a payer wants to 
invest in a relatively low-cost device that does not require extensive testing or regulatory 
approvals, and the payer has some ability to limit access to the new product. It may be less 
applicable to devices requiring more extensive testing or regulatory approval or drugs, where 
the costs of development may be higher or where the payer cannot control access to the new 
product. 
For more on hi HealthInnovations, see Appendix B. 
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PRODUCT CATEGORIZATION AND DIFFERENTIATION 
The methods that payers use to categorize and differentiate products can affect innovation by 
influencing pricing and utilization, creating distortions in the marketplace. Each payer categorizes and 
differentiates drugs and devices. Different approaches to product categorization or differentiation 
mostly have an indirect impact on EROI for innovative products, primarily by way of affecting behavioral 
incentives and market competition. The degree to which product categorization and differentiation is 
evidence-based is important. Ostensibly, payers establish formularies and categorize/differentiate 
products on the basis of evidence of clinical efficacy and safety, the existence of treatment alternatives, 
cost-effectiveness, acquisition cost, budget impact, and state and federal requirements and regulations.  
As such, these reimbursement decisions are supposed to represent value as a proxy for consumer 
welfare; i.e., what services, drugs, or devices a payer chooses to include in its medical benefit, or which 
drugs appear on the formulary (list of covered drugs) tell manufacturers what is of value to payers and 
consumers.57,58 Accordingly, prices and formulary parameters reflecting these categorizations may 
impact development of new products by influencing developers’ EROI. 
Differentiation can be effective in strengthening incentives to invest in valued innovation, as it may be 
used to reward more clinically effective or cost-effective products with higher prices or increased 
market share. Value-based approaches may reflect assessments of added effectiveness or other 
benefits, but they are only used by a minority of payers in the United States. Most explicitly evidence-
based approaches are found in Europe and Australia. For example, France, Germany, and the 
Netherlands, among other jurisdictions, have established so-called “premium pricing” for drugs and 
devices considered to be “highly innovative,” unlike non-innovative drugs which are subject to reference 
pricing. Notably, European jurisdictions have generally considered between 10% and 20% of newly 
approved drugs and devices to be “highly innovative.”59 
Table 4 summarizes the expected impact of numerous approaches to differentiation and categorization 
on pricing, drug utilization, distortions in the marketplace, and innovation; comments on several of 
these approaches follow the table. While different approaches taken to product categorization and 
differentiation may offer varying incentives for future innovation, much remains uncertain because 
empirical evidence is very limited. According to the experts consulted in the course of this study, many 
payers in the United States presently lack sufficient incentives, data, and leverage to limit coverage, 
payment, or utilization of products which offer little or no value added. There are more drugs available 
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on the market in the United States because of fewer restrictions, leading to more utilization and more 
pharmaceutical spending.60  
Table 4: Impact of different approaches to product categorization and differentiation on the 
marketplace and innovation 
Approach Impact on Pricing Impact on 
Utilization 












Drugs in medical 
benefit not subject to 
formulary; drugs 
under pharmacy 
benefit are subject to 
formulary 
 











on prices of drugs in 
classes with generics, 
leading to more 
consumer welfare 
 
More use of generics No In theory, more R&D 




Unknown – savings 
pass-through is not 
revealed 
Shift to preferred 
products on 
formulary 
Yes – because 
preferred formulary 
placement is not 
evidence-based 
 
Negative – due to 
rebates not being a 
function of value or 
evidence 
Value-based Approaches 
Exclusion lists Downward pressure 
on pricing of drugs in 
classes with excluded 
products 
 
Shift to included 
products 
Unknown; would 
depend on whether 
exclusion lists are 
evidence-based 
In theory, more R&D 





Limited, given low 




on products with 
little value added, 
higher prices for 
products with higher 
value  
Limited, given low 




products with little 
value added, more 
utilization for 




Not likely, except in 
the case of orphan 
drugs 




(e.g., clinically and 
cost effective, 
targeting areas of 
unmet need) 
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Approach Impact on Pricing Impact on 
Utilization 








Limited, given low 
numbers of enrollees 
affected 
Limited, given low 
numbers of enrollees 
affected 
Not likely In theory, more R&D 
in clinically and cost-
effective 
treatments, as well 





Limited, given low 
numbers of enrollees 
affected 
Limited, given low 
numbers of enrollees 
affected 
Not likely In theory, more R&D 
in clinically and cost-
effective 
treatments, as well 








Limited, given low 
numbers of enrollees 
Limited, given low 




effect onto other 
Medicaid programs 








Limited, given low 
numbers of 
enrollees; in theory, 
diagnostics will 
increasingly be priced 
in accordance with 
benefit provided to 
patients 
 
Use by Palmetto of 
diagnostics with 
proven clinical utility 
linking diagnostic to 
health outcomes 
Potential spillover to 
other Medicare 
contractors 




Source: authors’ analysis 
The choice of pharmacy versus medical benefit designation, generic substitution, and rebate 
mechanisms are methods widely used by payers, and they are the only approaches that appear to have 
a direct influence on sales prices. However, these three approaches are not necessarily evidence-based, 
and not directed at promoting value or innovation. This also implies that they are not conducive to 
bringing about investment in research targeting unmet needs. 
The prevalence of generic or therapeutic substitution may serve as an incentive to steer manufacturers 
away from incremental innovation and towards substantial or radical innovation, where the likelihood of 
substitution is much lower. Substitution of either kind may have a significant impact on pharmaceutical 
product development undertaking and focus. A recent empirical analysis found evidence of a negative 
relationship between generic penetration and early-stage pharmaceutical R&D activity within 
therapeutic classes; effects were stronger in classes where one might expect cross-molecular 
substitution to be relatively high (e.g., anti-infectives, anti-hypertensives, anti-histamines), and not 
statistically significant where substitution may be relatively low (e.g., neurological disorders).61 Low 
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 Branstetter, L., Chatterjee, C., & Higgins, M. (2014). Starving (or fattening) the golden goose? Generic entry and 
the incentives for early-stage pharmaceutical innovation. NBER Working Paper Series. Working Paper 20532. 
Retrieved from http://www.nber.org/papers/w20532 
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levels of R&D investment may also reflect a variety of other factors, such as lack of scientific or 
technological opportunities.  
Rebates may introduce marketplace distortions or deviations from optimal pricing and utilization, 
because it is unknown (considered proprietary information) how much of the negotiated rebate is 
passed on to end-users. Also, preferred products may not be the highest value products, and are not 
necessarily more cost-effective; the drugs’ preferred status is more likely to be a function of negotiating 
power on the part of payers and manufacturers, than of evidence of value.  
Theoretically, VBID could improve resource allocation and encourage development of high-value 
products that would get preferential treatment with little or no patient cost-sharing. At the same time, it 
could reduce incentives to invest in innovations to treat orphan diseases. This is because most orphan 
disease treatments are often not considered cost-effective or good value for money, as manufacturers 
charge high prices to offset relatively small prospective patient markets. Applications of VBID in the 
United States have been relatively few in number and narrow in scope, so there is little empirical 
evidence available to discern the potential impact on innovation from broader use. We looked at one 
example in our case studies, a pilot program of a value-based drug formulary by Premera Blue Cross 
(Box 2). 
There are many examples of CED implementation in international markets. In the U.S., Medicare has 
instituted CED programs for more than a dozen devices and a handful of drugs.62 The idea of only paying 
for health technologies that work at least as well in real-world settings as they do in clinical trials is 
intuitively attractive, and a downstream possibility with CED. With conditional access, manufacturers 
know that there will be some access to their new products upon regulatory approval. Investors 
anticipating this access will likely continue to invest in the products’ development. Alternatively, the use 
of CED could hinder incentives to innovate, given the fear of an additional post-marketing hurdle. There 
is anecdotal evidence that manufacturers may think this way.  
Risk-sharing arrangements could influence innovation by establishing a pricing model in which payments 
would be linked to value, as in a pay-for-performance arrangement. Firms would have to incorporate 
value end-points (demonstrations of innovativeness) in development should this pricing model become 
more widely used. Additionally, payments would be made over a period of time, during which health 
benefits are realized and measured. For example, pricing could be set as a flat per-patient price, 
regardless of the amount of the drug required to achieve the desired outcome, instead of the usual per 
dosage or per unit amount. The performance-based patient access scheme (PAS) for Velcade in the U.K., 
which was the focus of our third case study (see Box 3), illustrates the promise and challenges that these 
programs present.  
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 Centers for Medicare & Medicaid Services. (2015, April 10). Coverage with evidence development. Retrieved 
from http://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/index.html  
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BOX 2 | PREMERA BLUE CROSS: A VALUE-BASED APPROACH TO PRODUCT 
CATEGORIZATION & COST SHARING 
The value-based insurance design (VBID) concept gained significant attention after its 
introduction in the early 2000s in the form of a “benefit-based copayment.” Multiple 
experts consulted during this project recommended VBID as a reimbursement strategy 
worthy of further examination, in part because of its high profile. Although it has 
generated much interest, applications to date have largely been limited to a few large self-
insured health plans, targeting relatively few drug classes or health conditions, and mainly 
consisting of only cost-sharing reductions for “high value” drugs or conditions, rather than 
increases for “low-value” ones. Limited evidence from these applications indicates that 
these programs may improve use of and adherence to medications, but generally do not 
produce overall savings for health plans, at least not in the short post-implementation 
periods studied to date. 
Premera Blue Cross, a health plan from the northwestern United States and independent 
licensee of Blue Cross Blue Shield Association, recently piloted a value-based formulary 
(VBRx) for the drug benefit offered to its own employees. The Premera VBRx is 
comparatively novel and appears to be the broadest application of the VBID concept in the 
United States. Evidence from the initial roll-out of the program suggests that it is possible 
to implement VBID on a broader scale, with a design that may lead to modest savings for 
the health plan, without negatively affecting adherence to drug therapies for several 
common health conditions. 
Largely based on theory, VBID holds some promise to shift incentives toward development 
of “high-value” products. However, further evaluation of programs such as Premera’s VBRx 
is needed to determine how broader use may ultimately affect incentives in the 
marketplace that affect the return on investment for developers of new products, 
including sales volume, sales prices, and development costs. Longer study periods may 
help to tease out delayed effects on spending, health outcomes, or other factors. A 
broader focus on total costs to a health plan is necessary. An assessment of spillover 
effects is also important; where VBID applies to a particular category of services, such as 
drugs, but not others, there may be interactions with other reimbursement systems for 
other services. To date, the evidence base from Premera’s VBRx and VBID programs more 
broadly – at least that available in broadly-accessible public sources – is insufficient to truly 
understand how broader adoption may affect innovation for healthcare technologies.  
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BOX 3 | NICE (UK): PERFORMANCE-BASED REIMBURSEMENT FOR VELCADE® 
In its initial technology appraisal of Velcade® (bortezomib) in 2006, the National Institute 
for Health and Care Excellence (NICE) in the United Kingdom (UK) found the drug to be 
comparatively clinically effective, but not cost-effective vis-a-vis the usual standard of care  
(high dose dexamethasone or HDD). At £31,000 per life year gained and £38,000 per 
quality adjusted life year (QALY) gained, the estimated incremental cost-effectiveness 
ratios (ICERs) were substantially higher than the generally accepted ICER threshold in 
England of £20,000 - £30,000  per QALY.  
With the expectation that final guidance from NICE would be unlikely to support the use of 
Velcade in the UK National Health Service (NHS), the manufacturer (Janssen-Cilag) 
proposed an arrangement in which the NHS would pay for the drug only for patients in 
whom a pre-specified response to treatment was demonstrated. A ‘payment-by-results’ 
protocol was developed in which treatment response was gauged via a well-accepted 
tumor marker - an indirect measurement of tumor shrinkage - as a surrogate endpoint. A 
subsequent reconsideration of the medicine by the NICE appraisal committee, taking into 
account the impact of the proposed payment-by-results arrangement, gave rise to an 
anticipated ICER of less than £21,000/QALY, and the drug received a positive 
recommendation. 
Although not the first performance-based funding arrangement implemented in the UK, 
the Velcade Patient Access Scheme (PAS) was the first reimbursement protocol to involve 
rebates for treatment failure. As the NHS would be required to pay for the drug only for 
those patients who demonstrated an adequate response to treatment, the PAS effectively 
amounted to both a performance guarantee and a substantial price discount.  
At the original price proposed, Velcade did not meet the definition of an innovation that 
enhances consumer welfare in the UK. The PAS changed the effective price and allowed 
Velcade to meet the definition of a substantive innovation, albeit with an effect on the 
manufacturer’s expected return-on-investment (EROI). It is unclear whether performance-
based RSAs such as the Velcade PAS influence incentives to innovate, in part because of 
the lack of measured evaluation of this program and because of the challenges of designing 
and administering an outcome- or performance-based PAS. The vast majority of PAS in the 
UK since the Velcade example have been financially based arrangements; they are 
generally considered ways to reduce the price of a new technology to bring it in line with 
societal “norms” regarding cost-effectiveness. 
For more on the NICE PAS for Velcade, see Appendix D. 
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In the early 1990s, Oregon’s Medicaid agency established its “Prioritized List of Health Services” to set 
priorities for health service expenditure. Prioritization was based on the premise that medical 
interventions are not of equal value, and therefore a process is needed to decide what will be financed 
with public resources. Using an explicitly evidence-based decision-making process, the Oregon Health 
Evidence Review Commission (HERC) maintains the list, which ranks hundreds of condition- treatment 
pairs in order of clinical effectiveness and cost-effectiveness, and taking into account patient 
preferences. Treatments that prevent illness, provide maternity and newborn care, and manage chronic 
diseases are emphasized. As long as the condition being treated is included in the funded region, all 
associated diagnostic and ancillary services associated with it are assumed to be covered – including 
prescription drugs and medical devices. Prior to each legislative session, a biennial review and update of 
the Prioritized List is completed. Modifications are made at other times to issues corrections and include 
recent advancements in medical technology. 
The Oregon approach has received praise for its inclusive and relatively transparent decision-making 
process, but has encountered resistance from multiple stakeholders. Notably, although Oregon still uses 
the list, no other state or private payer has since adopted this approach, in part because of the 
controversy surrounding the explicit use of cost-effectiveness to prioritize services; opposition to the 
notion of not covering effective treatments because of cost, which draws on concerns about rationing; 
and the implications for items excluded from coverage.63 
The Medicare contractor Palmetto designed and implemented the Molecular Diagnostic Services 
Program (MolDx) as an explicitly evidence-based framework for decision-making on coverage and 
reimbursement of companion diagnostics. These are diagnostics used to stratify populations into those 
who will likely benefit, or are at risk of suffering adverse reactions, from a particular therapeutic. In 
November 2011, Palmetto instituted a payment system that assigns a unique code to molecular 
diagnostics, and at the same time, Palmetto released a coverage submission checklist for new 
diagnostics. Under Palmetto’s program, applicants must show that the diagnostic test has clinical utility, 
such as improvement in patient outcomes or changes in physician behavior for the management of the 
patient.  If applicants cannot demonstrate clinical utility, then the tests are not covered. To date, no 
other Medicare contractor has adopted a similar approach to diagnostic evaluation. However, some 
Medicare contractors are following Palmetto’s decisions for the sake of consistency, as are some private 
insurers. 
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METHOD OF PAYMENT 
The choice of bundled or per-unit payment by third-party payers primarily affects ROI by affecting the 
price that a manufacturer of a healthcare technology charges purchasers, either directly by affecting 
manufacturers’ pricing decisions, or indirectly by changing incentives for providers or other suppliers to 
select particular products. When payers use per-unit payments, the effects on the manufacturer’s return 
on investment and incentives to pursue innovative products are largely dependent on the method used 
to establish the payment level (see “Defining the payment amount,” p. 41). Consequently, this section 
mostly focuses on the question of how a shift toward bundled payments may impact incentives to invest 
in the development of new healthcare technologies. 
Bundled payments incentivize providers or suppliers to reduce 
their per-bundle cost, thereby increasing demand for products 
that reduce the cost of goods and services included in the 
bundle. Economic theory indicates that manufacturers’ list 
prices for these products should rise in response, although 
there is insufficient evidence to determine the size of the 
potential effect. Therefore, the shift to bundled payments is 
likely to have an inflationary effect on the prices of novel 
products that reduce costs borne by health care providers, 
regardless of whether those products provide comparative 
advantage in effectiveness. 
Importantly, bundled payments will only have this effect on 
healthcare technologies that are cost-saving from the provider 
perspective. Providers’ demand for these products increases 
under bundled payments because the incentive for cost minimization shifts from the payer onto the 
provider. A shift to bundled payments should not affect demand for healthcare technologies that reduce 
costs borne only by patients or society as a whole, such as technologies that reduce the number of days 
of recuperation at home and related days of work missed. 
Because bundled payments give providers incentives to clamp down on unnecessary or costly health 
services that cannot be billed on an itemized basis, they also have the potential to distort provider 
decision-making in favor of lower-cost technologies, even in cases where higher-cost options would be 
more appropriate or effective. To some extent, quality monitoring systems and focused evaluations can 
check for unintended effects on outcomes, as was done in the transition to Medicare’s prospective 
payment system for hospital care in the early 1980s.  
Where bundled payments are in place, exceptions are often made for products designated as highly 
innovative and/or high cost, with the result that default unit pricing is applied for those products. For 
example, Medicare uses “pass through” exceptions for drugs and biologics that have a cost per day in 
excess of a defined threshold. One expert panelist noted that, at least for products aimed at hospital-
based care, the use of pass-through payments and other add-ons to diagnosis related groups (DRGs) 
Expert’s quote: 
Increased use of bundled 
payment and episode-based care 
payment… will require a person 
to think differently in terms of 
what value do you actually add to 
this episode of care?  Are you 
[reducing] the cost of care? Are 
you improving the key metrics 
that will be measured as part of 
this episode of care? 
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(and similar bundled systems) could help to incentivize innovation where products may not fit into the 
existing reimbursement bundle, but could potentially reduce total costs of care. 
On the other hand, per-unit payment systems reward excessive provision of drugs and devices; a 
provider, prescriber, or supplier may have many reasons for choosing a particular product, but it is often 
the case that they benefit financially from the transaction. Therefore, per-unit payment systems can also 
distort provider decision-making with regard to appropriate utilization of healthcare technologies. 
Neither bundled payment nor per-unit payment would be expected to distort patient decision-making, 
except to the extent that they affect cost-sharing arrangements, which we discuss later (see p. 47). 
Patients are rarely aware of the method of payment used to reimburse the provider. 
However, a payer’s choice of payment method could affect overall availability and use of products by 
patients and providers, depending on design of the payment and insurance system. For example, 
research shows that the initial diffusion of magnetic resonance imaging technology in hospitals was 
slowed by Medicare’s DRG-based reimbursement system.64 In this case, rather than being driven by the 
extent of innovation offered by the novel product, the utilization was driven by the up-front outlay of 
the purchaser, with more costly technologies facing greater barriers in uptake. When identified, such 
barriers may be addressed on an ad hoc basis through payment exceptions and regulatory interventions. 
Table 5 summarizes the impact of the use of bundled payments versus per-unit payments on the prices 
of new healthcare technologies reflecting different levels of innovativeness. All of the described effects 
are hypothetical, based on an analysis of the incentives created under alternative payment approaches. 
Furthermore, without adequate information on where new products fall in terms of innovativeness and 
cost-savings, payers will not respond in ways that correspond with these expectations and markets will 
function less effectively and predictably. 
Table 5: Effects of per-unit and bundled payment methods on pricing of new healthcare technologies 
Method of 
Payment 
Novel products that are not 
innovative 
Innovative products 





































Source: authors’ analysis 
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 Hillman, A., & Schwartz, J.S. (1985, November). The Adoption and Diffusion of MRI and CT in the United States: A 
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Impact on pricing for products that do not qualify as innovations. Demand for novel products that are 
not innovative and fail to reduce provider costs should decrease significantly under a bundled payment 
system, as providers (e.g., hospitals deciding what scanners to buy) face strong financial incentives not 
to buy and use them. This should result in lower prices, in comparison to an environment characterized 
by per-unit payment. In the latter case, new products may be awarded a premium, presumed to be 
better than existing therapeutic alternatives by virtue of their novelty, irrespective of whether improved 
effectiveness can be demonstrated.65 
Impact on pricing for less innovative products. In the case of products that offer no or only minimal 
additional effectiveness over their marketplace competitors (i.e., non-innovations and incremental 
innovations that payers or prescribers view as largely the same as existing products), bundled payments 
are likely to pose downward pressure on average prices paid in the market. Buyers in these cases are 
likely to consider a range of products as suitable for use, and be in a relatively strong negotiating 
position. This expectation, however, has not been established empirically, and much depends on the 
extent to which buyers are incentivized to obtain the best possible value for money. For such 
(incrementally innovative) products, per-unit payment is less likely to exert comparable pressure. The 
provider or prescriber of the drug or device does not, under this method of payment, share a stake in 
the payer’s incentive to seek value, although this could be mitigated in cases where a payer utilizes a 
system of reference pricing to define a maximum reimbursement amount.66 
Impact on pricing for more innovative products. In the case of products that offer more-than-
incremental improvement in effectiveness over existing comparators (i.e., substantial or radical 
innovations), per-unit payments may be more likely to pose indirect pricing pressure by opening the 
door to negotiations with sellers, which may influence institutional purchasing and formulary 
management tools. However, the impact on prices is dependent on the degree of leverage that the 
payer brings to the negotiations. Furthermore, neither bundled payments nor per-unit payments can be 
seen to have an edge in putting price pressure on sellers of products that represent true 
“breakthroughs” or radical innovations, as buyers will have limited leverage unless empowered to reject 
or narrowly constrain coverage on affordability grounds. (This practice is not common in the United 
States). Per-unit payments may offer more scope to obtain price discounts, to the extent that payers are 
able to use the “threat” of more (or less) restrictive utilization management as leverage in negotiations 
with manufacturers or other suppliers. 
Broader use of indication pricing, episodic care pricing, or bundled payment would affect patterns of 
investment. The net prospective impact of a shift toward bundled payments on incentives to innovate 
with respect to various types of novel products is summarized in Table 6. Overall, it appears likely that 
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 An example would be an extended-release formula of an existing drug released just prior to patent expiry.  
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 In a study that examined prices of anti-hypertensive drugs in Canada, researchers found that (under a pay-per-
unit scheme) prices decreased as the number of products of the same family rose, but increased as the number of 
products in a competitive family increased. See: Benda, M.C., Lu, H., Mallory, C. (2004, May). An Econometric 
Estimation of Pricing of Brand-Name Drugs. Health Canada Working Paper. 
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shifting toward bundled payments has the potential to increase incentives to innovate in cost-reducing 
novel products, regardless of their level of innovativeness. Bundled payments should reduce incentives 
to develop non-innovative products that are not cost-reducing, as well as products representing 
incremental innovation. This shift is unlikely to have a meaningful impact on incentives for radical 
innovation, while the effect on investment in substantial innovations is uncertain and dependent on the 
strength and effectiveness of safeguards put in place to protect such innovations (e.g., pass-through 
payments, such as those used in Medicare to support hospital use of innovative biologics, drugs and 
other healthcare technologies). 
Table 6: Impact of shift to bundled payments on incentives to invest in the development of innovative 
healthcare technologies and other novel products 
 Novel products that are not 
innovative 
Innovative products  

































impact (in that 
radical 
innovations are 
likely to be 
exempt from 
bundles) 
Source: authors’ analysis 
Impact on investment in novel products that are not innovative. An attractive feature of the use of 
bundled payments is the disincentives they create to invest in the development of new products that 
are neither a) more effective than existing alternatives, nor b) cost saving from a provider perspective. 
Whereas such products stand a good chance of obtaining a foothold in the healthcare system under a 
per-unit payment scheme, they are significantly less likely to be adopted and diffused in a scenario 
where a provider bears responsibility for both excess costs and for maintaining quality of care, 
potentially in combination with pay-for-performance type incentives. Instead, healthcare technology 
developers who cannot demonstrate increased effectiveness will need to offer “value” through reduced 
costs, such as lower unit prices. 
As discussed above, bundled payments exert price pressure on products that do not offer substantial 
additional effectiveness over existing treatments in meeting significant health needs. While this is not 
necessarily problematic, it could be viewed as undesirable in cases where new additions to a class are 
sought, as in the case of antibiotics, for example.67  
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 To the extent such problems arise and are identified, it may be possible to address them through special 
regulatory interventions, as is done in the area of orphan drugs, for instance. 
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Impact on investment in cost-reducing technology. It is often stated that bundled payments, including 
DRGs and per-capita payments, will provide health plans and providers with incentives to demand new 
cost-saving technologies, and this demand will spur development of such products.68 One expert 
consulted in this project gave an example of how device developers shifted resources to try to find 
solutions that would reduce or avoid hospital-acquired infections in response to the announcement that 
Medicare would stop paying for care attributable to these infections, illustrating that firms will target 
investment to address a need identified by providers and/or payers (e.g., hospitals’ desire to reduce 
costs associated with infections). However, the role of technology in driving cost is complex; a 
technology that reduces the unit cost of diagnosis or treatment for an individual case may, in fact, 
increase overall expenditures as the reduced unit costs encourage higher overall utilization. 
Furthermore, the alignment of incentives remains a critical issue. Taking steps to reduce silos and 
encourage full assessment of a product’s comparative cost-effectiveness and budget impact could help 
ensure that bundled payments serve to incentivize development of new healthcare technologies that 
reduce costs to both payers and consumers. In this regard, we can draw insightful lessons from 
financer/purchaser models in which the incentive alignment problem is less pronounced, as is the case 
for closed or integrated systems like Kaiser Permanente and the Veterans Health Administration.69 
Impact on investment in innovative technologies. Perhaps the greatest uncertainty involves how a move 
to bundled payments would affect incentives to invest in innovative technologies. It could be argued 
that the incentives to invest in radical innovations remain unchanged, as such innovations are likely to 
be exempted from a bundled payment mechanism unless they have limited impact on the cost of the 
bundle. Additionally, payers are unlikely to restrict access to treatments that radically improve patient 
outcomes, especially if payment (or regulatory compliance or continued network participation) hinges in 
part on demonstrated performance. With respect to products that offer modest but meaningful 
improvement in comparative effectiveness over alternatives, such as substantial innovations, the 
prospective impact is less clear. A 2014 survey of payers sponsored by the medical device industry found 
that increasing use of risk-sharing and pay-for-performance payment models stands to shift the 
traditional paradigm, in which payers act as gatekeepers and providers act as patient advocates in 
obtaining access to new healthcare technologies, by better aligning payer and provider incentives.70 
However, only four of nine payers interviewed in that survey expressed a view that it would be more 
difficult for effective yet costly innovations to obtain approval for coverage because of these changes. 
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 Garber, S., Gates, S. M., Keeler, E. B., Vaiana, M. E., Mulcahy, A. W.,  Lau, C., & Kellermann, A. L. (2014). 
Redirecting Innovation in U.S. Health Care: Options to Decrease Spending and Increase Value. Santa Monica, 
CA: RAND Corporation. 
69
 An expert from a closed system consulted in panels convened for this study noted that her organization is able 
to adopt a long-run (10 to 15 year) view of potential benefits and costs of a new healthcare technology being 
considered for purchase/use that would not make sense for other payers, for example. 
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 Long, G., Mortimer, R., & Sanzenbacher, G. (2014, December). Evolving Provider Payment Models and Patient 
Access to Innovative Medical Technology. Journal of Medical Economics. 17(12); 883-893. 
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In any case, there are policy interventions that can serve to limit the potential of bundled payments to 
stifle innovation. These interventions include frequent revisions to the content of each bundle and the 
use of pass-through exemptions for innovations that meet designated criteria pertaining to effectiveness 
and/or cost.71 Bundled payments that come with mandates to measure and report certain quality 
metrics, possibly with bonuses/penalties tied to those metrics, might also affect incentives to innovate. 
Industry and investor panelists felt that wider use of bundled and episode-based payment would require 
developers to think differently about the “value” added by new technologies: for example, would a 
product reduce the total cost of care, or improve key outcomes or metrics measured by the payer(s) in 
conjunction with an episode of care? Although the panelists reached consensus on the importance of 
value, there was little consensus in the ensuing discussion of how to measure value. While some payers 
use quality-adjusted life years (QALYs), several panelists noted that this approach is full of challenges, 
such as incorporating the differing views of stakeholders on what constitutes quality of life (e.g., healthy 
people vs. those with serious illnesses or disabilities). Others noted that measures could focus on clinical 
improvements that improved patient health at a reasonable cost without invoking quality of life, but this 
approach still leaves unanswered questions about what constitutes a “reasonable” cost or even what is 
an “improvement” in patient health. The lack of consensus or clarity in definitions of these key terms 
highlights one of the challenges to broader adoption of bundled or episode-based payment 
mechanisms. 
DEFINING THE PAYMENT AMOUNT 
The methods used by payers to define payment amounts stand to affect prospective innovators’ 
expected return on investment primarily by influencing sellers’ pricing strategies. The method that 
stands to have most significant impact on consumers is therapeutic reference pricing, a form of internal 
benchmarking where the payment level is capped at a defined level for all pharmaceuticals judged to be 
therapeutically equivalent (or similar, in some cases). In this case, patients are required to pay out-of-
pocket to cover the difference between the price and the payment amount, which may cause 
prescribers and patients to favor lower-cost alternatives. Methods that yield higher relative prices may 
also have an indirect dampening effect on utilization by consumers, particularly where payers tighten 
eligibility for use due to budget constraints, or pass higher prices on to consumers through cost sharing. 
However, the evidence base is limited, so most of the linkages between the effects described in this 
section, expected return on investment (ROI), and various types of innovation remain largely 
hypothetical and uncertain. 
It is an unresolved matter of policy debate which methods yield lower prices. In principle, administered 
pricing, where prices are set by a policymaker or government regulator and not arrived at through 
negotiation between buyer and seller, can give rise to prices that are significantly lower than those paid 
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by other payers.72 However, the outcome depends on factors such as the administrator’s objectives 
(which may not be to obtain the lowest possible price); the formulae used to define payment amounts; 
and the product manufacturer’s willingness to forego or delay sales in order to secure or protect a 
desired price threshold.73 In the case of negotiated pricing, expert panels convened for this study 
broadly agreed that the payer’s negotiating strength depends both on the number of covered lives 
represented and the ability to employ formulary and utilization management tools to influence the 
volume of products used by beneficiaries.74 Conversely, the product manufacturer’s leverage reflects 
demand for the product by providers and patients, and the extent and strength of competition in the 
specific market niche the product serves. 
With EXTERNAL BENCHMARKING, there is a strong risk that manufacturers’ prices will be higher than 
would be expected in an optimally functioning market. For example, state Medicaid programs usually 
pay pharmacies based on list prices, but the amounts that manufacturers rebate back to states are 
based on (much lower) prices for sales to pharmacies and wholesalers, and Medicare pays for physician-
administered drugs using a formula based on the average sales price (ASP), plus a 6% mark-up. Both of 
these approaches establish incentives for manufacturers to charge high list prices, while offering 
discounts to buyers as competition warrants, because a higher price offers larger margins to dispensing 
physicians and pharmacies which may, in turn, affect use of particular treatments.75,76,77 Medicare’s fixed 
20% coinsurance provides only a weak constraint on pricing because most beneficiaries have 
supplemental insurance that covers coinsurance and often caps the patient’s financial exposure, leading 
to relative price insensitivity.  
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 Gellad, W.F., Schneeweiss, S., Brawarsky, P., Lipsitz, S., & Haas, J.S. (2008). What if the Federal Government 
negotiated pharmaceutical prices for seniors? An Estimate of National Savings. Journal of General Internal 
Medicine 23(9): 1435-1440. 
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 Pharmaceutical manufacturers often delay launch in markets where administered price levels are relatively low 
when they believe they will have a negative effect on the prices in other markets, due to parallel trade, the 
practice of external price benchmarking, or both. See OECD. (2008). Pharmaceutical Pricing and Reimbursement in 
a Global Market. 
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 Research has shown that commercial insurance benefited from implementation of Medicare Part D, because the 
increased number of covered lives represented by insurers gave them more leverage in pharmaceutical price 
negotiations. As a result, Part D lowered drugs prices for commercially insured patients by 5.8 to 8.5%. (Source: 
Lakdawalla, D.N., & Yin, W. (2010). Insurers’ negotiating leverage and the external effects of Medicare Part D. 
Review of Economics and Statistics.) 
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 Alpert, A., Duggan, M., & Hellerstein, J.K. (2013, August). Perverse reverse price competition: average wholesale 
prices and Medicaid pharmaceutical spending. National Bureau of Economic Research (NBER) working paper 
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External benchmarking also has significant spillover effects in terms of defining global price levels for 
new healthcare technologies. For example, the widespread practice of external benchmarking in the 
European Union has resulted in pharmaceutical manufacturers launching new products first in countries 
that a) allow manufacturers to set their own prices, or b) in countries where relatively high launch prices 
are common. This enables manufacturers to establish higher prices for their products throughout 
Europe.78 Medicaid’s mandatory drug rebate program, which requires companies to provide substantial 
discounts and match the “best price” given to non-governmental payers, has been similarly criticized for 
reducing discounts to commercial payers.79,80,81 
Higher prices tend to lead to relatively high payment levels under external benchmarking, with market 
shares awarded to products on the basis of novelty alone, as opposed to value or relative effectiveness. 
This occurs because sellers are adept at using techniques to obtain inflated market prices, such as 
strategic sequencing of market launch and requiring confidentiality with respect to rebates. These 
inflated prices are then subject to benchmarking by other payers. An example cited by experts consulted 
for this project was the proton pump inhibitor (PPI) Prilosec, and its successor, Nexium. The 
manufacturer of Prilosec (omeprazole) introduced Nexium (esomeprazole) after Prilosec’s patent 
expired, while simultaneously taking steps to delay introduction of generic version of Prilosec to the 
market. Through this launch, the manufacturer was able to establish a high sales price and market share 
in the United States for the follow-on product, even though Nexium offered minimal, if any, added 
benefits over Prilosec.82 
LOWEST POSSIBLE PRICE STRATEGIES seem likely to produce spillover effects for payers who pay 
based on external benchmarking. In the case of pharmaceutical manufacturers, a common strategy for 
sellers is establishment of a narrow range of acceptable public prices on a global basis and having 
confidential negotiations with purchasers over rebates or discounts. In practice, this likely means that 
payment levels reflect market leverage and negotiating capacity rather than willingness and ability to 
pay for products that offer a given set of benefits. 
Lowest possible price methods may encourage over-investment in products that offer little or no added 
value. For such products, there is often less uncertainty about the potential market for the new product, 
because of observable payment amounts for close competitors and other factors, such as a clear 
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placement within the existing code sets used to determine payment amounts in inpatient, outpatient, 
and other provider settings. 
In cases where payers have little or no leverage, such as with highly innovative products for which there 
are no therapeutic alternatives (and where payers are not empowered to reject coverage on non-clinical 
grounds), the lowest possible price payment method is equivalent to external price benchmarking. 
Prices are set at a common public price with no confidential discounts or rebates granted. By using 
market leverage to pay the lowest possible amount for a product, payers risk fostering incentives to 
under-invest in radical innovation and cost-saving technology if developers or investors fear that these 
technologies will be undervalued. 
By contrast, there is evidence that using INTERNAL BENCHMARKING (also called therapeutic reference 
pricing) to establish payment levels can influence manufacturers to reduce the sales price of less 
innovative products. In Germany, manufacturers were, until recently, free to establish prices for 
pharmaceutical products sold in the country; however, social insurers’ payment levels for new products 
were limited to the price of products judged to be therapeutically equivalent, including off-patent 
products and their generic equivalents. Patients were required to pay out-of-pocket for any additional 
cost for higher priced products. In many cases, after a product was assigned to a therapeutic reference 
group, its manufacturer lowered the sales price to avoid risking reduction in the product’s market share, 
due to comparatively high cost-sharing.83 Based on these observations, internal benchmarking will tend 
to result in lower payment levels for products that offer little to no added value in terms of enhanced 
effectiveness or cost savings associated with use. EROI for such products will be lower in an 
environment where many payers, or a few payers representing significant market share, are using 
internal benchmarking to establish payment levels. 
Danzon and Ketcham have argued that reference pricing would “likely have a more negative effect on 
prices of on-patent products because of the more competitive U.S. generic market, and on research and 
development and the future supply of new drugs, because of the much larger U.S. share of global 
pharmaceutical sales,” if systematically applied in the United States.84  
In theory, VALUE-BASED METHODS of determining payment amounts should decrease payment 
amounts (at least the payer’s share) for novel products that are not innovative or cost-reducing, while 
potentially increasing payment amounts for innovative products, commensurate with the level of 
additional benefit. Value-based pricing also provides the greatest potential to increase incentives to 
invest in substantial and radical innovations. In principal, value-based methods that define payment 
based on an assessment of benefits offered, whether in terms of added effectiveness or improved cost-
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effectiveness, could yield the highest prices for radical innovations as a reward for furnishing new 
benefits. Manufacturers may themselves price radical innovations at a level that reflects the benefits 
offered.85 However, existing applications of VBID are relatively few and generally narrow in scope, 
providing insufficient empirical evidence to identify effects on ROI and/or innovation (see Box 2 and 
Appendix C). 
With internal benchmarking and value-based pricing, any premium awarded reflects an assessment of 
added effectiveness or other benefits to society, the patient, or the payer. For example, the Arkansas 
State Employee Benefits Division used a reference pricing system for Nexium, which limited the 
reimbursement payment level for esomeprazole to the amount it paid for generic omeprazole ($.90 in 
2005). This approach accrued savings of $7.2 million over the subsequent 43 months, in comparison 
with PPI costs of health insurance plans that were not using reference pricing.86 Internal benchmarking 
and value-based pricing are less likely to have spillover effects, although the pricing decisions that result 
from use of such methods may be referenced via external benchmarking approaches.  
Value-based pricing provides potential to increase incentives to invest in substantial and radical 
innovations. Payment methods that define the amount paid based on an assessment of benefit offered 
are not widely used for a number of reasons, including technical challenges and the perceived risk of 
adopting an approach that could result in higher payments, particularly for products offering substantial 
benefits. However, some experts have noted that these value-based methods may reduce market 
distortions in supply and demand for healthcare goods and services. Danzon and colleagues analyzed 
alternative arrangements for establishing pharmaceutical payments in countries with universal 
insurance coverage, which distorts the market and constrains the ability to attain maximum static 
(short-term) and dynamic (long-term) efficiency:87  
..if each payer unilaterally sets an incremental cost effectiveness ratio (ICER) threshold 
based on its citizens’ willingness to pay for health; manufacturers price to that ICER 
threshold; and payers limit reimbursement to patients for whom a drug is cost-effective 
at that price and ICER, then the resulting price levels and use within each country and 
price differentials across countries are roughly consistent with second best static and 
dynamic efficiency. 
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Skeptics of value-based payment raise concerns about the limitations of explicit thresholds or anchor 
points for value, and point out that existence of such measures would lead to pricing that gravitates 
toward the threshold from levels both above and below. At present, only a handful of payers are 
pursuing value-based strategies to define payment levels, although there is some experimentation in the 
United States with value-based insurance design (in which benefits, rather than payments, are defined 
according to an assessment of relative value).88 Sophisticated approaches, such as performance-based 
risk-sharing arrangements, may allow for greater experimentation with such approaches in the future. 
Table 7 summarizes the relationships between methods of defining payment amounts, expected ROI, 
and incentives to research and develop innovative products. 
Table 7: Impact of method used to define reimbursement amount on expected return on investment 
in healthcare technologies 
 Novel products that are not innovative Innovative products 










Likely to increase 




Likely to increase 




Likely to increase 






















Impact unclear Likely to reduce 




Likely to reduce 











Likely to increase 




Likely to reduce 




Most promising approach for yielding ROI that is 
equivalent to value (as judged from consumer, payer 







Likely to reduce 




Impact unclear Uncertain. There is significant risk that this payment 
method will over-incentivize investment in 
incremental innovations and under-incentivize 
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PATIENT COST SHARING 
Different levels and methods of cost sharing primarily change incentives for consumers to use services 
and products. Despite the relative wealth of studies concerning effects on consumers, there are scant 
evidence-based research or evaluation studies that make the subsequent linkages to ROI or future 
innovations. Nevertheless, certain conjectures can be made from an understanding of cost-sharing 
features, such as how changes in consumer demand or payer leverage might translate into changes in 
sales prices and/or sales volumes, which are key components of ROI/EROI. 
EFFECTS OF INCREASING/DECREASING COST-SHARING LEVELS 
Economic theory predicts that increasing cost sharing (or adding it where there is none) leads to lower 
demand for products and services because the patient faces more of the cost of care. Empirical 
literature indicates that adding or increasing cost sharing for prescription drugs typically reduces 
utilization, including appropriate use, and may lead to higher costs for other services.89,90,91 One 
literature review identified a broad range of estimates of the elasticity of demand for medical services 
with respect to cost sharing, including estimates of -0.1 to -0.6 for prescription drugs.92 Another review 
found that increased cost sharing is associated with lower rates of drug utilization and poorer adherence 
to ongoing treatments in a wide range of therapeutic areas; generally, a 10% increase in cost sharing 
results in a 2% to 6% decrease in prescription drug spending, regardless of the cost-sharing method.93 
Responses to changes in cost-sharing levels vary widely, depending on factors such as the underlying 
medical conditions and/or socioeconomic status of users. In one study, doubling the cost sharing 
amount resulted in a 23% decline in use of anti-diabetic drugs, compared with declines of 10% for 
hypertension drugs and 8% for antidepressants.94 A study of statin use among Medicare beneficiaries 
found that increasing out-of-pocket costs from $200 to $240 reduced the rate of adherent beneficiaries 
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from 67% to 56%.95 Conversely, eliminating cost sharing for medications prescribed following myocardial 
infarction increased adherence and decreased patient spending without increasing overall health 
costs.96 The effects of cost sharing on utilization are relatively strong among low-income populations, 
who are more price sensitive.97,98,99,100,101 However, even among low-income patients, responses may 
differ across drug classes.102 
Economic theory suggests that increases in utilization, which result from increases in consumer demand, 
imply increased pricing power for sellers, and generally exert upward pressure on prices. Put together, 
these effects suggest sellers’ expected revenues increase as cost sharing falls. Except in cases where cost 
offset programs are used (see Box 4), the manufacturers’ total costs of development, manufacture, or 
sale of a healthcare technology are not affected by patient cost sharing. This implies that ROI also 
increases as the overall level of cost sharing declines. Although increased ROI creates opportunities for 
firms to increase investment in R&D, prior research suggests that cost sharing may not produce a 
differential impact for R&D focused on development of innovative products, compared to novel but 
non-innovative products.103 
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BOX 4 | COST-SHARING OFFSET PROGRAMS 
Drug manufacturers have responded to recent growth of cost-sharing levels by introducing cost-
sharing offset programs, which alter financial incentives for insured patients by subsidizing their 
out-of-pocket costs through coupons, rebates, or direct reimbursements. According to industry 
sources, cost-offset programs are rapidly growing the United States, with 561 such programs 
covering 708 brand-name drugs identified in early 2014, a 34% increase compared to mid-2012.i 
These programs appear to engender opposition from third-party payers when they affect choices 
between competing products on different cost-sharing tiers, such as between a preferred brand-
name drug and a non-preferred brand-name drug.ii Experts consulted during this project noted 
that in such cases, the manufacturer’s discount to the consumer undermines the cost-sharing 
structure (which tends to favor products that are less expensive for the payer) and negatively 
affects the power of payers in negotiations with manufacturers. Moreover, the manufacturer only 
offers the discount for patients who request and qualify for assistance, and not for every sale 
covered by the payer (as is likely to be the case with agreements that affect tier placement). Third-
party payers may view cost offset programs more favorably when they apply to products that are 
clinically effective and save money elsewhere in the system, or where they apply to high-cost 
products for which payers would likely require high levels of cost sharing anyway. In these cases, 
the offset programs become an indirect way of capturing discounts from manufacturers. 
Notes: 
i. Zitter Health Insights. (2014, March). Co-pay offset monitor. As described in: Fein, A. (2014). A new reality 
check on co-pay offset programs. Retrieved from http://www.drugchannels.net/ 2014/03/co-pay-offset-
programs-are-blooming-in.html 
ii. Visante, Inc. (2011, November). How copay coupons could raise prescription drug costs by $32 billion over 
the next decade. Prepared for the Pharmaceutical Care Management Association. 
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Conversely, increased cost sharing reduces utilization and confers less pricing power for sellers, pushing 
revenues and ROI downward. Recent growth in Part D and commercial plans with four or more tiers 
reflects efforts by plans to pass on at least part of the high costs of certain drugs to insured patients. For 
example, plans have been largely unable to negotiate formulary rebates and price discounts for 
biologics, in part because these products cannot be replicated precisely and, until 2015, no biosimilar 
products had been approved by the FDA. These products frequently end up on the highest cost-sharing 
tiers, which frequently use coinsurance of 25%-40% or more of the cost of the drug.104,105,106 
Industry and investor experts consulted in this study noted that increased cost-sharing levels is a 
universal problem, with little room left for inflating costs to the patient, especially among the highest 
cost/highest use patients. One posited that effects may differ between technologies that produce 
effects the patient can feel (e.g., reduced pain), versus therapies aimed more at prevention where the 
benefits are less obvious/immediate.  
Although existing research focuses primarily on drug classes and not specific drugs, the variation in 
effects observed across different classes suggests that cost sharing (of any type) may have smaller 
effects on use and pricing of innovative products, especially substantial or radical innovations as defined 
in this project. By definition, these products confer greater benefits to patients in comparison with 
existing therapeutic alternatives, or they address a more significant previously unmet or inadequately 
met health need, so demand for them is potentially more inelastic. Any effects on utilization are also 
likely to be smaller for products that target more severe conditions, compared to those for less severe 
or asymptomatic conditions, regardless of whether the product is determined to be innovative or not. 
Differential cost sharing offers the potential to reward more valuable innovations over less valuable 
innovations, to the extent that cost sharing is higher for products offering lower consumer welfare 
enhancement and lower for products offering more consumer welfare enhancements. Experts we 
interviewed noted the possibility of value-based reimbursement with lower copays for more “value” – 
although this led to a discussion among several panelists of the pros and cons of QALYs and other ways 
of measuring value, which highlighted that defining what constitutes value is a challenge and often 
controversial. In the cases offered as examples by panelists, the payer defines and determines what 
“value” is, but the process is not always transparent to outside observers. 
There is also no evidence that assessments of value from a consumer or societal perspective are the 
basis for most formulary placement decisions that determine cost sharing levels. Plans typically apply 
lower cost-sharing amounts to incentivize use of preferred (often less expensive) services, such as 
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primary care physicians instead of emergency rooms for non-emergent care, or preferred products, such 
as generic drugs. Higher cost-sharing levels usually apply to non-preferred products and services. For 
example, most commercial plans require higher cost sharing for services and devices from non-network 
providers (and may not cover such services at all). A more recent trend is that commercial, Part C, and 
Part D plans are beginning to use tiered cost sharing to distinguish between preferred and non-
preferred providers within their networks.  
COPAYMENTS VS. COINSURANCE 
Coinsurance may have greater effects on utilization, even when configured to achieve the same cost-
sharing levels as fixed copayments. Theoretical models suggest that copayments lead to better 
adherence with prescription drug regimens than variable coinsurance, by reducing patient uncertainty 
with regard to out-of-pocket payments. Based on a national sample of privately-insured patients using 
drugs for diabetes, adherence declined by 23% following a large increase in coinsurance, but adherence 
only fell by 9% after a comparable increase in fixed copayments.107,108 
Even relatively low coinsurance rates may create a financial burden for users of expensive non-preferred 
and specialty drugs. To some extent, maximum out-of-pocket provisions alleviate this burden, but not 
until consumers pay substantial sums out-of-pocket (usually several thousand dollars). Very high cost-
sharing levels may reduce the ROI for manufacturers of high-cost and specialty drugs, as the cost sharing 
weakens demand and reduces sales.109,110 These products may not meet the definition of consumer 
welfare-enhancing innovations used in this project, although they frequently target serious and chronic 
conditions.  
The greatest potential effects from cost sharing may occur where coinsurance (cost sharing applied as a 
proportion of the price, rather than a fixed amount) applies to high-cost, yet innovative products. 
However, neither copayments nor coinsurance seems likely to have significant effects on innovation. 
One reason is that manufacturers are in a relatively strong position to establish initial prices for their 
products in the United States, and they frequently employ sophisticated pricing models that enable 
them to account for anticipated cost sharing. Manufacturers’ cost-sharing offset programs also may 
mitigate effects, and the willingness of drug makers to participate in these programs on a relatively large 
scale suggests they are willing to accept lower rates of return on a per-unit basis for certain transactions, 
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in exchange for maintaining higher list prices for other transactions and greater sales volume to bolster 
ROI. 
DEDUCTIBLES & COVERAGE LIMITS 
With deductibles, consumers pay the full, approved amount for any services or products to which the 
deductible applies, until their out-of-pocket costs reach the deductible limit. Theory posits that 
deductibles will discourage unnecessary use of services, because they expose consumers to the full 
prices of these items. Empirical studies indicate that, in practice, increasing deductibles likely decreases 
use of unnecessary or inappropriate services and desirable and appropriate services, such as preventive 
care, until the consumer reaches the deductible limit.111,112 Studies also suggest that use of prescription 
drugs decreases where prescription drugs are subject to the deductible, but effects may be tempered 
for more severe conditions.113,114 These findings suggest possible reductions in utilization of drugs and 
devices that patients pay for directly. Deductibles are unlikely to affect use when the cost of the drug or 
device is part of an inclusive rate. 
It is unclear whether deductibles affect selling prices. They may incentivize manufacturers to set higher 
prices to push patients past the deductible limit more quickly. There is no evidence suggesting that any 
potential effect would differ between non-innovative and innovative products, although innovative 
products are more likely to command higher prices generally (with or without deductibles) due to higher 
demand. Considering these potential effects, deductibles seem unlikely to have significant effects on the 
ROI/EROI for innovative products relative to non-innovative products, or incentives for development of 
innovative products. 
Coverage limits, where insurance stops paying after a patient incurs total health care costs exceeding an 
annual or lifetime threshold, are relatively rare. Patients face the full cost of drugs and services above 
the limit, but people reaching the limits are likely to have serious chronic or acute conditions and little 
incentive to cease treatment. Coverage limits are unlikely to affect developers’ decisions about pricing 
or whether to invest in potentially innovative healthcare technologies, as the limits are rare and tend to 
be quite high, relative to the cost of any single healthcare technology.  
Table 8 summarizes the effects described in this section. 
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Table 8: Effects of cost-sharing approaches on ROI and incentives to invest in development of 
healthcare technologies 
 Novel products that are not innovative Innovative products 








 Likely to decrease use 
 Some price-reducing pressure, 
particularly for products that are not 
cost-reducing 
 Should reduce ROI and incentives to 
invest 
 Likely to decrease use 
 Some price-reducing pressure 
 Effects may be smaller for substantial and radical 
innovations if demand for those products is 
relatively inelastic 
 Unlikely to have substantial effects on ROI or 
incentives to invest in innovative products 
Decrease cost-
sharing level 
 Likely to increase use 
 Some price-increasing incentive 
 Should increase ROI 
 Unlikely to have differential effects on incentives for innovative vs. non-innovative products 




 Likely to have larger effects on use than copayments, especially for high-cost products 
 Potential for price-reducing pressure, particularly for high-cost products  
 Price and use impact may be offset by manufacturer cost-offset programs 
 Net effects on ROI are unclear 
 Although effects may be greater than with copayments, coinsurance is still unlikely to have 
significant effects on incentives to invest in innovative products as long as manufacturers 
are able to set higher prices for these products to counteract the effects of lost sales due to 
cost sharing, or use cost sharing offset programs to help patients afford the out-of-pocket 
costs and reduce the volume of lost sales 
Deductible  May affect use, particularly for high-
cost products 
 Effects on sales prices and ROI are 
unclear, but probably small 
 No clear expected effects on 
incentives to invest 
 Effects on use, pricing, or ROI are unclear, but 
probably smaller than for non-innovative 
products or incremental innovations. 
 Unlikely to have significant effects on incentives 
to invest  
Coverage limit  Unlikely to affect use, pricing, or ROI for individual products 
 No expected effects on incentives to invest in either innovative or non-innovative products 
(based on current prevalence and size of limits) 
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CONCLUSIONS 
Although it is widely accepted that the extent and nature of product reimbursement is a significant 
factor in the development decisions of potential developers of novel healthcare technologies and the 
investors who finance them, there is only limited empirical evidence of connections between 
reimbursement and innovation per se. Analysts posit that payment policies influence the diffusion of 
new products, and as a result have a substantial impact on R&D decisions and whether companies 
choose to advance a technology to market.115 Experts consulted during this project agreed that 
reimbursement is an important factor in R&D and investment decisions; that it is a critical factor in 
determining which products in development are brought to the market; and that its influence appears 
to be growing in importance. However, several experts questioned whether reimbursement policies and 
practices can truly steer developers and investors toward innovative products. Reimbursement is just 
one of many factors that may influence developers’ ability to innovate. Scientific opportunities are very 
important – a developer cannot produce a breakthrough product if the science is not there. A focused 
push by government or private organizations for new products in a particular area, such as an orphan 
disease, may also carry significant weight. For example, the Orphan Drug Act of 1983 and the FDA’s 2014 
guidance to industry on expedited programs for serious conditions reflect government efforts to 
encourage innovation.116 Patient groups are also developing patient registries to generate data about 
their diseases, and pressuring developers to focus on unmet needs. 
The question of how payers can foster innovation in healthcare technologies that improve consumer 
welfare could also be taken to imply that payer policies are ipso facto discouraging or impeding it. 
However we did not find evidence that this is likely to be the case. On the contrary, experts consulted on 
this project suggested that very few substantial or radical innovations are held back; generally, it was 
hypothesized that payers are willing to pay more for these types of products (e.g., one panelist 
described payers as willing to reward developers for “going into a whole new therapeutic area, and 
doing something quite special”). If this is the case, the questions then become: are incremental 
innovations being held back; if so, which ones; and, if they really are of value, how do we move them 
forward in development and get payers to recognize their value? Although by definition substantial and 
radical innovations offer greater advances relative to existing standards of care, a series of incremental 
innovations can add up to significant therapeutic progress. 
Our research indicates that reimbursement policies and practices affect key components of ROI for 
developers and investors, such as prices and sales volumes, and change incentives for many other actors 
in the marketplace that indirectly influence ROI. However it remains unclear precisely how these 
impacts ultimately affect innovation. There is a dearth of empirical evidence pertinent to the links 
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between reimbursement and ROI for developers (or investors). It is difficult, if not impossible, to 
measure and control for all potential variables in an experimental setting. In addition, many 
characteristics, such as bundled payments, are relatively new phenomena in the U.S. and therefore do 
not offer much documented experience or outcomes. Long timelines for development also muddy the 
effects (at least the ability to track them), particularly for drugs, biologics, and vaccines. We found no 
empirical evidence to directly connect reimbursement policies and practices with the quantity or quality 
of healthcare technology innovation. 
Our analytic framework, shown in Figure 2 on page 12, illustrates the connections between 
reimbursement policies and practices, and ROI for developers (and investors). Although there are direct 
paths of influence, including impacts on manufacturers’ selling prices and/or sales volume, or the costs 
associated with the development, manufacture, or sale of their products, the connections are not direct 
in most cases. The distribution systems for healthcare technologies involve many actors. The actions of 
providers, wholesalers, PBMs, and other intermediaries affect ROI for manufacturers, as they often 
receive a portion of the reimbursement. These intermediaries can also influence the reimbursement 
policies and practices used by payers; for example, healthcare providers make many decisions on behalf 
of patients and thereby influence product uptake. Intermediaries also may have different views from 
patients or third-party payers in terms of what constitutes value, or even the level of innovation 
(incremental, substantial, or radical) offered by a particular product. This complexity makes effects 
harder to determine and often ambiguous. In addition, the complexity of the U.S. healthcare system, 
diversity of approaches to reimbursement around the world, and the global nature of the drug and 
device industries create potential for unintended impacts from reimbursement policies and practices.  
The hi HealthInnovations advance market commitment (AMC) case study illustrates the potential 
effectiveness of establishing a direct link between reimbursement and a desired innovation. In this case, 
UnitedHealth Group filled an unmet need for hearing aids among its patients and the broader 
population by partnering directly with a manufacturer. The result was a set of devices with features the 
payer valued at price points that enabled more patients to afford the technology. The hearing aids 
developed in this case were relatively low-cost devices that did not require extensive testing. Broader 
applications of the AMC concept may be limited because of the greater development demands for more 
complex devices or drugs, and lack of ability for a single payer to control access to these types of 
products. 
Because the connection between reimbursement and innovation is usually not as straightforward as in 
the hi HealthInnovations case, this research project examined how five characteristics of reimbursement 
policies and practices may impact developers’ ROI and incentives to innovate: the reimbursement 
decision-making process; approaches to product categorization and differentiation; method of payment; 
methods of defining payment amounts; and patient cost sharing. The U.S. retains a pluralist framework 
with regard to the reimbursement decision-making process – hundreds of payers use their own 
assessment approaches to reach their judgments, leading to considerable variation. While variation may 
be appropriate for the different populations they serve, the lack of uniform decision-making weakens 
the ability of all but the largest payers to motivate developers to develop innovative products. The 
effects of different decision-making processes are hard to trace. Theoretically, processes that are 
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transparent and evidence-based will provide the clearest signals to developers and favor development 
of products that address unmet needs and/or provide added value over existing therapies. 
There is limited evidence concerning the effects of different approaches to product categorization and 
differentiation. Value-based approaches may reflect assessments of added effectiveness or other 
benefits, but a minority of payers in the United States uses them. There is optimism about the promise 
of value-based methods to align incentives for developers with the interests of patients, providers, and 
payers, but there are also many challenges to overcome. For example, although the experts interviewed 
in this project reached near consensus on the importance of accounting for value, there was little 
consensus in the ensuing discussions of how to measure value, what constitutes a “reasonable” cost, or 
even what is an “improvement” in patient health. The lack of consensus or clarity in definitions of these 
key terms highlights one of the challenges to broader adoption of value-based approaches. Different 
payers are likely to have varying definitions of innovation and value. Determinations of value may be 
case-specific. 
The case study of the Premera Blue Cross value-based formulary pilot program highlights some 
additional challenges for value-based approaches. For example, even with a systematic approach to 
measuring value, payers may lack access to data, research evidence, or other information necessary to 
determine who should receive treatment and in what circumstances. Limited availability of evidence 
may prevent optimal placement of drugs or other treatments. Quantifying the return for payers is also 
challenging. 
Whereas the reimbursement decision-making process sets the parameters for availability, prescribing, 
and reimbursement of drugs and devices, and methods of product categorization and differentiation 
help to distinguish among products, the next two characteristics – the method of payment and methods 
of defining payment amounts – determine the structure and size of payments for new technologies. 
While payment methods vary, the fundamental distinction is whether payers compensate providers or 
suppliers of healthcare technologies on a per-unit basis or as part of a bundled payment for a package of 
goods and services used for a clinically-defined episode of care. Per-unit payments seem unlikely to 
favor development of any particular type of innovation, but may also be ineffective at discouraging 
development of non-innovative products. A shift to bundled payments from per-unit payments may 
incentivize development of cost-reducing products (from the perspective of the payer), but may 
discourage incremental innovations.  
Theoretically, broader use of value-based or outcomes-based reimbursement would lead to lower 
returns on products and services offering little value added, higher returns for products with higher 
value, and greater clarity about where the value-added is uncertain. This could potentially increase 
incentives to invest in R&D aimed at products more likely to be deemed substantial or radical 
innovations, or at least it could stimulate investment in the identification of biomarkers that could be 
used as proxies for the clinical outcomes of interest in outcomes-based reimbursement. 
The case study of the performance-based risk-sharing agreement for Velcade in the U.K. illustrates some 
of the challenges in establishing performance-based payment. (Performance-based payment is closely 
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related to value-based or outcomes-based reimbursement, and involves use of a specific outcome target 
that is considered a way of attaining value-for-money.) For the manufacturer, there is the uncertainty 
about whether the drug will perform as expected, whether the outcomes achieved in a highly controlled 
clinical trial environment can be replicated in every day clinical practice.117 It also highlights the practical 
challenges, such as the identification of a clearly defined, objective metric of treatment effect 
(performance) that is either a direct measure of clinical outcome (such as survival or cure) or a well-
accepted surrogate endpoint that closely corresponds to or reliably predicts the desired treatment 
effect and is unaffected by other treatments. For payers, there is also a burden of measuring and 
monitoring patient progress, and there may be the challenging prospect of having to withdraw coverage 
of a drug either entirely, or in individual patients, depending on the nature of the risk-sharing 
agreement. The vast majority of patient access schemes (PAS) in the U.K. subsequent to Velcade have 
been financially-based arrangements, which are perceived as being simpler to administer than the 
outcome- or performance-based PAS.118 
The effects of reimbursement on innovation may also be muted by the ability of developers to 
strategically price their products. Manufacturers’ pricing models take into account expectations about 
lost sales due to higher costs or cost sharing; complex and secretive rebate and discounting mechanisms 
favor high list prices; and cost sharing offset programs reduce the negative effects on demand when 
payers apply patient cost sharing. Patient cost sharing does not appear to be an important barrier to 
innovation at present, at least for substantial or radical innovations. However, with growing levels of 
patient cost sharing, broader use of coinsurance, and very high list prices for new products, the balance 
may tip if utilization drops more than manufacturers anticipate or can compensate for with cost-sharing 
offset programs, or if manufacturers lose pricing power.  
SUGGESTIONS FOR FUTURE RESEARCH 
The direction and magnitude of effects on innovation resulting from most of the reimbursement 
characteristics and three specific cases examined in this project remain unknown or uncertain, in part 
because many of the effects reimbursement may have on innovation are indirect. Because there is no 
centralized entity in the United States that establishes standards for defining what constitutes value or 
that promotes investment in particular innovations, researchers focusing on the U.S. context are left 
with a selection of initiatives from the private sector and public demonstration projects.  
In-depth case studies that look at specific approaches to reimbursement may help to reduce some of the 
uncertainty about how reimbursement acts to incentivize or deter development of products that are 
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more likely to meet the definition of innovation used in this project. A well-designed and extensive case 
study approach is the most likely to provide insights into all aspects of innovation, given the relative 
scarcity of empirical evidence in the published literature. The expert panels we convened for this project 
provided a rich level of insight into the diverse beliefs about the relationship between reimbursement 
and innovation. 
One example of a broader case study could be an extension of the value-based insurance design (VBID) 
case study to include more payers. Premera is one of several private payers and employers that have 
launched VBID initiatives, and the Medicare Advantage Value-Based Insurance Design Model announced 
by CMS in September 2015 should provide additional opportunities. A comparison of the different 
designs could provide insights into the differences and similarities between these programs, particularly 
in terms of decisions concerning coverage and payment for drugs and devices. Indication-based pricing 
is another concept that has recently garnered interest, for example as a way to link prices of oncology 
drugs to their benefits.119 Indication-specific pricing is not yet being applied in the U.S., but a case study 
could examine emerging models, such as the American Society of Clinical Oncology’s conceptual 
framework to assess the value of cancer treatment options, or the Memorial Sloane Kettering Cancer 
Center’s DrugAbacus (http://www.drugabacus.org/).120 
There are several initiatives from the CMS Innovation Center announced or underway that may serve as 
opportunities to evaluate how drug and device developers respond to bundled payments and other 
reimbursement approaches focused more specifically on payment methods. These include the Health 
Care Payment Learning and Action Network, and episode-based payment initiatives such as the Bundled 
Payments for Care Improvements (BPCI) and the Comprehensive Care for Joint Replacement Model. 
Ultimately, the impact of reimbursement on innovation hinges on the decision-making processes of drug 
and device developers. A potential research study might involve a well-designed questionnaire of senior 
R&D decision-makers about how their discovery and clinical development programs would differ under 
various hypothetical reimbursement policies and programs, assuming they become universal or at least 
widespread, and how they think that their target product profiles (TPPs) would be affected under these 
scenarios. The questionnaire might be coupled with in-depth individual interviews of at least a subset of 
survey respondents. The scenarios for this study could be derived from the case studies described 
above. The willingness of R&D leaders to participate in such an analysis is uncertain. However, such a 
study could offer a peek into the “black box” of decision-making within organizations engaged in drug 
and device development. 
Future research could also focus on implementation barriers related to use of comparative effectiveness 
research findings. As noted in our assessment of Premera Blue Cross’ value-based formulary, several 
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people involved in that program’s roll-out were concerned by how often requests for economic data 
from manufacturers were unmet, and it is resource-intensive for individual payers to assess the 
available information. The Patient-Centered Outcomes Research Institute (PCORI) and other federal 
programs are generating more comparative effectiveness evidence, and more private sector entities are 
allocating resources towards comparative effectiveness. But, whether this is having or will have an effect 
on prescribing patterns, and whether it is having or will have an effect on product development remains 
to be seen. 
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APPENDIX A: A STANDARD REIMBURSEMENT DECISION-MAKING PROCESS 
The approach to reimbursement decision-making is how payers make decisions on which drugs, devices, 
and other healthcare technologies to make available to patients, at what price, and for whom. The 
following steps are illustrative of a typical decision-making process by a P&T Committee or other 
decision-making body. 
1. Clinical evaluation. Typically, payers will review FDA documents providing details of efficacy and 
safety of new molecules or biologics; they may also review the published literature and clinical 
trial reports. Where comparative effectiveness evidence is available, this may also be considered 
provided the comparisons are relevant and reflect current treatment patterns. Devices are 
evaluated using a similar set of measures, although industry experts consulted during this 
project noted that CMS coverage decisions are crucial for devices because other payers 
frequently follow those decisions. Committee members typically seek to address the following 
questions: 
a. Is there compelling evidence of a need to add this drug to the formulary, or to cover the 
device? 
b. What is the quality of the evidence submitted for approval (and comparative evidence, 
if available)? 
c. Does the new product address an unmet or inadequately met need? 121 
 
2. Coverage of the drug or device under the medical or pharmacy benefit. This administrative 
decision has numerous implications for drug and device reimbursement, as payers may use 
different methods of payment; different methods to establish the amounts that they will pay for 
a product; or different patient cost sharing depending on the designated benefit package (we 
discuss all of these characteristics in more detail later in this Appendix).  
 
3. Potential for misuse. The committee examines the possibility for expansion of indications, which 
could include supplemental approvals as well as off-label uses of new drugs, and inappropriate 
use of devices. Accordingly, the payer may tag new drugs and devices with prior authorization or 
other utilization controls.  
 
4. Economic evaluation. The committee may assess a new drug or device’s total cost to the payer 
and cost-effectiveness relative to existing treatment alternatives. In this context, the committee 
asks whether the additional costs of the drug or device are justified by the additional benefits 
expected. Industry and investor panelists viewed the increasing focus of payers/providers on 
cost and health care economics as a key development, making bottom-line impact assessments 
increasingly important. They noted that the expanding evidence requirements for new products 
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in the U.S. and the rest of the world complicate the process of bringing technologies to market 
and add cost and uncertainty to the process. 
 
5. Approval or rejection by the committee. The committee makes the binary choice whether to 
cover a drug or device. 
 
6. Development of drug and device-use conditions. For covered items, the committee establishes 
conditions of reimbursement, such as patient cost-sharing, prior authorization, quantity limits, 
and step therapy requirements. Rebates are often a key driver of the development of drug-use 
conditions. Payers negotiate rebates from manufacturers in exchange for their ability to move 
market share. In this context, payers assign preferred status, such as lower patient cost-sharing 
or fewer conditions of reimbursement, to products on the formulary in exchange for rebates. 
For most payers, pricing information is confidential, but it is known that pricing decisions are 
made during this phase of formulary management. 
 
7. Drug and device-use monitoring and follow-up review. The committee reviews drug and device 
claims and utilization data, in addition to medical claims where appropriate.  
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APPENDIX B: HI HEALTHINNOVATIONS CASE STUDY 
BACKGROUND 
The advance market commitment (AMC) concept gained traction in the early 2000s as a potential means 
to encourage the development of new vaccines and treatments for neglected diseases.122,123,124 The 
rationale was that diseases such as malaria and tuberculosis primarily affect developing countries, which 
limits the commercial value of products targeting those diseases.123 By guaranteeing a market, or 
removing at least some of the uncertainty about the size of the market, and therefore the projected 
revenues, these commitments theoretically encourage more firms to invest in development of the 
desired product(s). Observers note that the incentives for manufacturers may vary depending on the 
structure of the agreement, such as “winner-take-all” or “multiple winners” approaches; front-loaded or 
back-loaded financial incentives; and guarantees of quantity or guarantee of price only.122 Others raise 
concerns that particular setups may require contributors to guarantee to pay for potentially medically 
inferior products.125 “Bounties” or awards may be other, similar approaches to encourage development 
of such products by providing a financial reward for production of a particular drug or device. 
There are differences between the initial AMC concept and the hi HealthInnovations hearing aid model, 
but both concepts are, at their core, formal agreements by a payer or other organization to guarantee a 
vendor (or vendors) a viable market for a product viewed as desirable by payers, or, more broadly, by 
society. Through an agreement with IntriCon Corporation, a developer and manufacturer of body-worn 
medical and hearing devices, hi HealthInnovations established a line of custom hearing aids with 
features it deemed necessary, at a price point that expanded the hearing aid market to many new 
consumers. This case is an example of direct investment by a third-party payer to develop a device 
tailored to its specifications, with a goal of improving health outcomes and reducing costs.  
Experts consulted for this project noted that greater sharing with developers of information on what 
items and services are being used and at what cost to payers would likely lead to new innovations 
developed to reduce those costs, and target improvements on the most costly issues within particular 
patient groups. However, commercial payers in the United States operate in a competitive business 
environment, where it is unlikely for open sharing of cost information to take place. Current efforts to 
expand all-payer databases and develop new tools to analyze “big data” sources, such as electronic 
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medical records, may make efforts to identify payers’ unmet needs more feasible in the future. In the 
absence of such data sharing, developers are more reliant on payers and consumers to send signals 
about the types of products they value. An advance market commitment clearly indicates a desire for a 
particular innovation. 
OBJECTIVES/RATIONALE OF HI HEALTHINNOVATIONS   
Lisa Tseng, MD, CEO of hi HealthInnovations, offered several reasons for the development of the hearing 
aid devices and related benefit program(s). One objective was to respond to a significant unmet need, 
both among UnitedHealthcare health plan participants and the general U.S. population. 126  The 
prevalence of hearing loss increases by age, with more than 40 percent of people age 60 or older in the 
U.S. having loss in at least one ear, per World Health Organization criteria.127 The National Institute on 
Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health (NIH), 
estimates that about 25 percent of the population between the ages of 65 to 74 and 50 percent of the 
population aged 75 and older have disabling hearing loss. The NIDCD also estimates that just 30 percent 
of adults ages 70 and older who could benefit from hearing aids, and only 16 percent of adults from ages 
20 to 69 who could also benefit, have ever used them.128 Studies indicate that hearing loss leads to 
lower workforce productivity and social isolation, and is associated with higher rates of depression and 
cognitive decline, as well as other mental health concerns.129 Researchers have also observed a 
relationship between hearing loss and increased risk of falls.130 
Additional objectives for hi HealthInnovations were to improve access to hearing care and reduce the 
price of hearing aids for all consumers and for people enrolled in the UnitedHealthcare’s commercial, 
Medicare Advantage, and stand-alone Medicare prescription drug plans (PDPs). Along with affordable 
health insurance and prescription drugs, Dr. Tseng noted that affordable hearing aids are one of the 
most frequently-requested services among health care consumers.126 One reason is cost: health 
insurance coverage for hearing aids is often limited, and costs for these devices can be high. Media 
reports cite average out-of-pocket costs to consumers ranging from $1,000 to $4,000, and pricing for 
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specific hearing aids may be much higher.131,132 Pricing can also be confusing, with some prices including 
bundled services such as fitting, adjustment, and follow-up care, and other prices reflecting just the 
purchase of the device itself. The traditional Medicare fee-for-service Medical Insurance program (Part 
B) does not cover routine hearing exams, hearing aids, or exams for fitting hearing aids; coverage of 
hearing aids is excluded by statute. Some Medicare Advantage (Part C) managed care plans cover them. 
Hearing aids and related care are covered services in Medicaid. 
In addition to making hearing aids more affordable and accessible, hi HealthInnovations wanted to offer 
a line of products that gave consumers the benefit of advanced technologies, offering high-quality sound 
and customizable settings for individual users, while avoiding “unnecessary” features.133 The company 
wanted the hearing aids to be easy to use, particularly for older consumers and technophobes; another 
objective was delivery of the hearing aids in a consumer-friendly manner. 
KEY CHARACTERISTICS OF HI HEALTHINNOVATIONS  
In 2011, hi HealthInnovations reached an agreement with IntriCon to develop and manufacture a set of 
lower-cost hearing aids, using behind-the-ear and new (at the time) in-the-canal technologies. All of the 
new hearing aids are “air conduction devices,” which are Class I medical devices and exempt from the 
Food and Drug Administration’s (FDA) 510(k) submission process.134 Theoretically, such technologies 
require fewer resources and time to develop because they do not need to demonstrate substantial 
equivalence to an approved device, or go through a full scientific and regulatory review process. 
By working with its own hearing health professionals and primary care providers in UnitedHealthcare’s 
national networks to offer hearing testing, hi HealthInnovations was able to program and dispense 
hearing aids custom-tailored to people via a direct-to-consumer distribution channel, removing 
distribution intermediaries that may drive up costs. Moreover, in contrast to traditional hearing aids 
where support was often available only from the original local supplier, UnitedHealthcare’s size made it 
possible to support the devices nationwide through its care provider network or hi HealthInnovations 
staff, including in-person, over-the-phone, or online.  
UnitedHealthcare announced the new hearing aid program in October 2011, during the open enrollment 
period for Medicare Advantage plans. The hearing aids were fully covered or offered with a low co-
payment to consumers in those plans, depending on the plan chosen by the consumer. It was not long 
before the hearing aid discount was available to people enrolled in UnitedHealthcare’s commercial plans 
as a fully covered or low co-payment benefit. At the time, it was a unique offering among major U.S. 
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Medicare and commercial payers. While other insurers provided some coverage for hearing aids, this 
program stood out with its direct-to-consumer sales model and low out-of-pocket costs. The high level 
of observed demand led hi HealthInnovations to expand its offerings to non-UnitedHealthcare 
consumers and to develop “turn-key” programs, which enabled employers to directly adopt the discount 
program, while enabling other health plans to also participate. 
The hi HealthInnovations program offered relatively low out-of-pocket costs for hearing aids, compared 
to traditional distribution channels. The hi HealthInnovations website listed retail prices of $799-$999 
for these products in late April, while Medicare Advantage plan participants can access the devices for 
cost-sharing amounts ranging from no cost to $450 per aid. 
In addition to offering a selection of hearing aids for purchase online from hi HealthInnovations, the 
program initially included an online hearing test. The intent of the online test was to increase access to 
hearing care by enabling consumers to test their hearing at home. The test results provided information 
necessary for the company to customize hearing gain levels on new hearing aids before shipping them 
to customers. The online test was removed from the market shortly after launch due to regulatory 
issues, discussed later in this report. hi HealthInnovations now provides hearing tests through a staff of 
audiologists and hearing health professionals, and a network of contracted care providers; prospective 
customers may also use hearing test results from their own care providers. hi HealthInnovations staff 
noted that the company recently earned a U.S. patent for a hearing test kit that is available to health 
care professionals for $179, compared to other in-office tests that retail for more than $1,000. Many 
UnitedHealthcare network care providers can access the kit at no cost. 
HOW MIGHT BROADER USE OF PROGRAMS SUCH AS HI HEALTHINNOVATIONS  INFLUENCE 
INNOVATION IN DRUGS OR MEDICAL DEVICES? 
Dr. Tseng noted that achieving cost-effectiveness in developing the hearing benefit and the associated 
testing and follow-up care was a significant hurdle in developing the hearing aid program. In part, it was 
initially developed for individuals subscribed to UnitedHealthcare’s Medicare Advantage plans, and the 
benefit needed to be affordable for those plans under their existing reimbursement levels. 
Innovation, as defined for this research project, is a function of the extent to which a drug or device 
addresses a disease or condition for which there is a substantive (i.e., non-trivial) unmet or inadequately 
met need, and whether, and to what extent, the new product offers clinically meaningful benefits 
compared to existing treatments. By this definition, the hi HealthInnovations hearing aids produced by 
IntriCon may be “incremental” or even “substantial” innovations; they target a potentially significant 
unmet need that can improve consumers’ quality of life and may help to reduce medical and behavioral 
health expenditures. IntriCon asserts that the new hearing aids offer improved benefits over existing 
technologies at comparable price points, such as better clarity and greater ability to filter out 
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background noise.135 If so, they may offer increased net health benefit compared to existing, similarly-
priced aids. The aids also appear to be consumer welfare-enhancing, by being offered at a price that 
more patients are willing to pay. Payers and consumers often cite the high cost of hearing aids sold 
through traditional channels as a significant barrier to broader adoption, so the lower cost of IntriCon’s 
devices factors into their value-add assessments. 
The conceptual model for this research project establishes expected return-on-investment (EROI) as a 
proxy for incentives to innovate and posits that current returns on investment are viewed as indicative 
of potential future returns. Our framework for analysis notes that reimbursement policies and practices 
can affect EROI (or ROI) directly by establishing a particular payment level, which in turn affects average 
sales price; by setting a volume of sales at that payment level; and/or by influencing the seller’s costs 
associated with development, manufacture, or sale of a healthcare technology. Reimbursement policies 
also stand to indirectly influence EROI/ROI by establishing different incentives for key actors, including 
patients/consumers, dispensers, care providers, sellers, and payers. These incentives, in turn, affect 
effective price, volume and, in some cases, seller costs.  
The agreement between IntriCon and hi HealthInnovations is proprietary, so details are not publicly 
available. IntriCon’s investor documents suggest that the agreement required a sizable ramp-up of 
production to cover an anticipated surge in demand following the program’s launch and to meet 
ongoing demand thereafter, with negotiated sales prices for those products.135 By pre-negotiating rates 
with the developer, hi HealthInnovations provided consumers with a hearing aid benefit with little or no 
out-of-pocket costs, at a much lower cost to the payer (UnitedHealthcare) than hearing aids in the 
traditional channel. This type of arrangement would have directly affected IntriCon’s EROI by 
establishing a sales price and offering the company assurance that a large number of potential 
customers would gain access to its hearing devices and be able to afford them, virtually assuring a 
substantial increase in sales. United Health Group does not disclose business unit-specific results, but Dr. 
Tseng said that “large numbers” of consumers have taken up the benefit.136  
IntriCon developed the hearing aids at the request of hi HealthInnovations, spurring innovation with a 
promise that sales would follow. Direct investment by payers or other organizations in the development 
of a potential technology is not a guarantee of successful innovation. Developers may face numerous 
hurdles during research and development or commercialization, such as scientific challenges, regulatory 
delays or failures, and unexpected economic costs that reduce the economic value of the new product, 
relative to any clinical benefits. However, the risks of these adverse events are almost certainly lower for 
Class I devices such as the hearing aids in this case.  
Even if an innovative product is successfully developed and brought to market, the payer and developer 
may not achieve the desired benefits/returns envisioned in the initial agreement. Depending on the 
structure of the agreement, the returns may also fluctuate due to market conditions that are hard to 
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predict. Adverse selection is a potential concern for payers with a unique offering in the market, as they 
may attract disproportionate numbers of people who want and need the new product. Although 
selection may be a minor concern with a hearing device, it could be significant with technologies 
targeting expensive treatments or sicker patient groups. Another risk is that competing developers may 
bring a superior – more innovative – product to market. For the payer, the agreement may lock them 
into using the inferior product. For the developer, the competition may reduce the potential market for 
the product developed under the advanced market commitment. In its 2015 annual report for investors, 
IntriCon noted that several of the firm’s competitors “offer more standardized and less technologically 
advanced products at lower prices,” and that competition negatively affected the firm’s sales and 
margins.137 
Sales of the innovative product may represent a large share of the developer’s revenues. Although it is 
an established company, IntriCon’s most recent annual report notes that the firm depends on five 
customers for about 57 percent of its net sales; the largest customer accounts for almost two-thirds of 
that amount.137 Although IntriCon does not disclose that hi HealthInnovations is one of those top five 
customers, it is an important one. Net sales in IntriCon’s hearing health business increased by 13.2 
percent in calendar year 2012, the first full year of the hi HealthInnovations program.138 Net sales fell by 
17.1 percent in 2013, which IntriCon primarily attributed to reduced purchases by hi HealthInnovations 
and weak hearing device sales in conventional channels.139 Net sales rebounded in 2014, growing by 
16.3 percent, because of strong sales to hi HealthInnovations and conventional channels.137 
By removing at least some of the uncertainty about the size of the market, and therefore the projected 
revenues, an advance market commitment theoretically encourages firms to invest in development of 
the desired product(s). It is not clear how the agreement with hi HealthInnovations affected IntriCon’s 
level of investment in efforts to develop new products. IntriCon’s filings for investors state that the 
company conducts research and development (R&D) activities primarily to improve existing products 
and proprietary technology, including technologies in the hi HealthInnovations devices, to spur long-
term revenues and margin growth.137 The manufacturer reported R&D expenditures of $4.9 million in 
2011, $4.5 million in 2012, $4.2 million in 2013, and $4.8 million in 2014.137,138,139  These amounts 
represent between 7 and 8 percent of total net sales over this period (Figure B1). The variation in the 
ratio of R&D spending to total net sales does not align with trends in total sales, using either the same 
year’s sales or sales in the preceding year. While it is reasonable to assume that the additional revenues 
from hi HealthInnovations bolstered recent R&D budgets, IntriCon attributed the drop in R&D spending 
in 2013 primarily to receipt of tax credits and global restructuring – not lower sales.  
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As noted, the incentives for manufacturers may vary depending on the structure of the agreement. An 
approach similar to the design of hi HealthInnovations, which appears to be primarily a guarantee of 
price only with some assurances about quantity, may work best in circumstances where a payer desires 
a particular product and maintains control over access to that technology once it reaches the market. hi 
HealthInnovations is the sole source for the specific hearing aids it contracted with IntriCon to produce. 
This winner-take-all approach assured IntriCon of significant sales volume up front, while hi 
HealthInnovations paid discounted rates. As such, this arrangement was beneficial to the payer 
(UnitedHealth Group) and the developer (IntriCon). However, the arrangement carries risk for IntriCon 
because it does not guarantee a minimum amount of purchases from hi HealthInnovations, those 
purchases can cease at any time, and it limits the company’s ability to sell hearing aids or accessories to 
another health insurer or directly to consumers.141 The risk to hi HealthInnovations appears to be low, at 
least with regard to the agreement for the hearing aids, given the characteristics of the agreement 
disclosed by IntriCon. The primary risk to hi HealthInnovations appears to be underutilization of the 
                                                          
140
 IntriCon Corporation. (2012). Form 10-K annual report filed 3/14/12 for the period ending 12/31/11. Retrieved 
from http://investorrelations.intricon.com/secfiling.cfm?filingID=897101-12-440 
141
 IntriCon Corporation. (2013). Form 10-K annual report filed 3/13/13 for the period ending 12/31/12. Retrieved 
from http://investorrelations.intricon.com/secfiling.cfm?filingID=897101-13-348 
142
 IntriCon Corporation. (2014). Form 10-K annual report filed 3/12/14 for the period ending 12/31/13. Retrieved 
from http://investorrelations.intricon.com/secfiling.cfm?filingID=897101-14-317 
143




Page | 69 
 
benefit or increased competition in the “value” hearing health market, which would reduce return on 
the investment in setting up the program. 
Market competition and regulatory challenges are other potential hurdles that may affect the volume of 
sales, either directly or by changing incentives for prescribers and consumers. Shortly after launch, hi 
HealthInnovations faced opposition from hearing care providers. The American Academy of Audiology 
and the Academy of Doctors of Audiology voiced concerns about the lack of intervention by professional 
audiologists, the validity of the online hearing test and representation of the devices as a “cure” for 
hearing loss.144,145 These and other organizations representing audiologists and hearing instrument (aid) 
specialists argued that direct-to-consumer sales violated state dispensing laws and practices.145 Other 
hearing-related organizations, such as the Hearing Loss Association of America which represents 
consumers, were more supportive of hi HealthInnovations as a way to expand access to hearing health 
care and hearing aids.146 
Responding to complaints, the FDA investigated the online hearing test and determined that it was a 
medical device, and it had not received FDA approval prior to marketing. hi HealthInnovations was 
ordered to cease marketing the online test.147 The FDA’s decision did not prohibit marketing and sales of 
the hearing aids, only the online hearing test developed by hi HealthInnovations. However, this decision 
likely contributed to the drop-off in IntriCon’s hearing health sales by reducing consumers’ access to 
testing that was necessary before obtaining the new devices. hi HealthInnovations eventually developed 
a new hearing test kit for use by primary care physicians, nurse practitioners, physician assistants, and 
other licensed medical professionals.  
Although the initial opposition to this new model by hearing health provider groups focused on 
consumer protection, it also reflects a common reaction when the established providers of a drug, 
device, or related service see a new product or business model as a threat to their own businesses. 
Opposition by provider organizations seems to have waned over time; several of the aforementioned 
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organizations sent a joint statement to care providers in August 2012 about how to work with programs 
such as hi HealthInnovations.148 
The hi HealthInnovations approach, led by a single company, may be best suited to fostering innovation 
in Class I medical devices. In contrast, this approach may not be as well suited to drugs. If a payer 
invested directly in the development of a new drug product, it would not be possible for the payer, or a 
subsidiary, to be the exclusive supplier of the drug. A large private payer might be able to get a 
significant price concession, but use of external benchmarking or administrative pricing schemes by 
other payers may limit the extent of discounts. For example, Medicaid’s “Best Price” provision requires 
manufacturers to sell drugs to Medicaid at the lowest price offered to commercial payers, in most cases. 
The private payer would therefore invest in a product that would benefit other payers and society more 
broadly – including those that did not invest in the product. It is unlikely that this model is feasible for a 
lone commercial payer to use to promote innovation of a new drug. Similarly, a larger coalition would 
almost certainly be necessary to drive development of Class II or Class III devices that require more 
extensive testing and regulatory approvals, which would generally increase research and development 
costs. Other conditions would also need to be present, such as well-defined endpoints for measuring 
benefits, and data and infrastructure to do so.149 
Coalitions of multiple payers, social organizations, or governments may still find the AMC approach 
feasible for development of products that produce social gains, as illustrated by the GAVI Alliance 
(formerly, the Global Alliance for Vaccines and Immunization) and its Pneumococcal Vaccine Advance 
Market Commitment Program for vaccines in developing countries. Research on a pilot program 
suggests that this model accelerated the roll out of new vaccines to developing countries.150 Critics of 
the GAVI program argue that programs that expand use of existing vaccines targeting more common 
diseases, rather than development of new ones for less common conditions may save more lives for less 
money, or that traditional discount purchasing mechanisms such UNICEF may be less expensive.151 
However, the AMC approach appears to work well as a mechanism for bringing specific advances to 
market, relatively quickly. 
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CONCLUSION 
In sum, the hi HealthInnovations hearing aid program is a case in which a payer observed a significant 
unmet need among its subscribers and the general population. Believing that meeting that unmet need 
would produce happier customers, health benefits, and potentially lower health care costs, 
UnitedHealth Group invested directly in a product and distribution model meant to fill that gap. Based 
on the definition of innovation used in this project, the hearing aids offered by hi HealthInnovations 
might best be deemed incremental innovations. The advance market commitment and new distribution 
model, rather than the devices, may be the greater innovations, which helped to make hearing aids 
more affordable and accessible. The specific approach in this case seems most appropriate for similar 
instances where a payer wants to invest in a relatively low-cost Class I device and has some ability to 
limit access to the new product. A broader coalition would likely be necessary for the model to work as a 
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APPENDIX C: PREMERA VALUE-BASED FORMULARY CASE STUDY 
BACKGROUND 
Originally termed the “benefit-based copay,” the intent of VBID is to align patients’ out-of-pocket costs 
with the expected clinical benefits of products or services, relative to costs.152,153 With VBID, patients 
who are expected to gain the greatest benefit from a product or service pay lower out-of-pocket costs 
than patients expected to achieve more modest or minimal gains. Economic theory posits that insurance 
coverage encourages greater consumption of health care products and services by reducing patients’ 
out-of-pocket costs. One of the arguments in favor of cost sharing is that it may reduce 
overconsumption by incentivizing patients to avoid “low-value” services – that is, where the total costs 
outweigh the clinical or health benefits. However, patients generally do not have the time, aptitude, 
access to resources, or motivation to accurately weigh the benefits and costs to themselves, much less 
from an insurer’s or societal perspective. Consequently, patients tend to reduce use of all types of care 
when cost sharing is applied, not just “low-value” services. By reducing cost-sharing levels for “better” 
or “more effective” care, and raising cost-sharing levels for less effective care, VBID theoretically steers 
consumers towards these options and leads to more appropriate use and better outcomes.152 
One rationale for VBID is to increase patient adherence to beneficial medications and potentially achieve 
savings (or at least cost neutrality) through reductions in the use of high-cost services such as 
emergency room visits and hospitalizations. As documented in other reports from this project, many 
studies indicate that lower cost-sharing levels are associated with more use of medications and services 
and better adherence to continuing therapies, while increases in cost sharing are associated with 
reductions in use and adherence, even for “high-value” care.154 
In theory, cost sharing in a VBID program should vary according to individual circumstances.155 Economic 
theory also suggests that, for a given level of value, cost sharing generally should be lower if demand is 
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inelastic, such as for chemotherapy, and higher where it is more elastic.156 Observers have noted in the 
past that a cost sharing system with such a significant degree of complexity may not be practical on a 
broad scale because of the high costs of setting up and maintaining the necessary administrative 
systems; the paucity of information from which to assess value; and the difficulties of real-time 
communication of clinical information and cost-sharing amounts between payers, care providers, and 
consumers.157 These concerns still appear to be valid, although they may lessen as electronic record 
systems and data sharing become more common. 
Given these challenges, there are two typical approaches to VBID in practice. One approach reduces cost 
sharing for products and services determined to have greater clinical value irrespective of individual 
patient characteristics. For example, Pitney Bowes, a large U.S.-based employer, moved asthma inhalers, 
beta blockers, and statins to its lowest cost tier in 2001. The second approach targets patients with 
particular diagnoses, offering reduced cost sharing for specific services deemed likely to offer more 
value. The city of Asheville, NC, and the University of Michigan used this approach in their VBID 
offerings, specifically targeting employees with diabetes. Aetna operated a program that combined 
elements of VBID (free or reduced cost sharing) and disease management for post-myocardial infarction 
patients. Early adopters typically only reduced cost-sharing levels for products and services deemed 
more valuable, and did not raise cost-sharing levels for other products to compensate.158 
Regardless of the particular approach, VBID requires a clearly-defined, formal system of assessing value 
– in terms of benefits relative to costs – to determine the appropriate copayment level.156 The 
perspective of the benefit designer, which may be a third-party payer and/or plan sponsor, is critical 
because that point of view will be a strong determinant of the definition of “value.” Although the 
definition could incorporate social equity or other concerns, the interests of a third-party payer may not 
align with a societal perspective. 
RATIONALE AND OBJECT IVES FOR PREMERA’S VBRX 
Discussing the rollout of VBRx at a 2013 conference, Prof. Louis Garrison, a health economist from the 
University of Washington and member of the Premera Value Assessment Committee, noted that health 
plans and their sponsors face rapidly rising drug benefit costs, with so-called “specialty drugs” a major 
driver of growth.159 He noted that “typical” responses by plan sponsors include changing benefit designs 
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to increase patients’ cost-sharing amounts and/or shift to consumer-driven models with high 
deductibles or health savings accounts (HSAs). These changes put the onus on members to be more 
responsible for their own health care utilization; payers may also put in place patient education, disease 
management, or other programs focusing on primary or secondary prevention to support these efforts. 
Prof. Garrison also noted that traditional pharmacy benefit designs use formularies based on the type of 
drug, such as single source or multiple source, preferred or non-preferred.160 “Value” in this context 
tended to be limited to the assessment of net unit costs. 
The Premera VBRx program seeks to separate high value drugs from low value ones. A stated objective 
is to develop a formulary based on incremental comparative effectiveness, where “value” incorporates 
assessments of both clinical value and cost.160 Some of the guiding principles were: 
 The design should be evidence-based, following the guidance of a decision-making committee 
made up of internal and external experts; 
 The process should be transparent, and take into account input from practicing physicians and 
other providers, and; 
 It should explicitly incorporate health economic data.160  
CHARACTERISTICS OF THE PREMERA VBRX PROGRAM 
Two committees formally evaluate each drug to determine coverage and placement on the Premera 
VBRx. The first is the Pharmacy and Therapeutics (P&T) Committee, which consists of seven physicians, 
three pharmacists, a pharmacy benefit manager, and a lay member – none of whom may be Premera 
associates.160 The P&T Committee examines the clinical benefit of products, including efficacy and 
safety. The detailed clinical review includes synthesis of evidence from multiple sources, peer review of 
the evidence, and presentation of findings during a formal P&T Committee review. Although the P&T 
Committee may consider cost in cases where there are multiple therapies deemed to have comparable 
clinical benefit, no formal economic evaluation occurs at this point.161  
The second committee is the Value Assessment Committee (VAC), which determines a drug’s value and 
tier placement. The VAC includes four economists, two practicing clinicians, a bioethicist, and one 
member of the public.161 The diversity of the membership reflects the fact that the VAC considers the 
quality of evidence for comparative effectiveness; effects on other medical costs and quality of 
life/productivity; and societal values including patient preferences, equity, and end of life care. 
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The VAC assessments rely on “credible” sources of data and results from cost-effectiveness analyses, 
such as manufacturers’ models; published economic studies and systematic reviews (e.g., Cochrane 
reviews); data from the Cost Effectiveness Analysis Registry compiled by the Center for the Evaluation of 
Value and Risk in Health (CEVR) at Tufts Medical Center; and reviews from assessment organizations in 
other countries, including the National Institute for Health and Care Excellence (NICE) in the United 
Kingdom and the Canadian Agency for Drugs and Technologies in Health (CADTH).162 To prepare for the 
VAC meetings, reviewers examine the evidence; develop specifications for cost-effectiveness model(s); 
build, run, and test model(s) for sensitivity to different assumptions; and then synthesize the evidence 
into a monograph for peer review and presentation to the VAC.163 Premera developed assessments for 
drugs in the 25 highest-volume drug classes used by its members, representing approximately 75% of 
drug utilization in the plan.162 Drugs in classes that were not assessed received a tier assignment based 
on their placement in the standard formulary used in Premera’s other drug plans.162  
The Premera VBRx strays somewhat from the ideal VBID structure in that the amount of cost sharing 
does not explicitly account for the value of the specific service for a particular patient. The latter would 
be difficult and resource intensive to implement and maintain, as it would require tailored assessments 
of value. Instead, the VBRx benefit has four tiers, based on each drug’s incremental cost effectiveness 
ratio (ICER), which is measured as cost per quality-adjusted life year (QALY) of the drug generally, not for 
a specific patient. Premera created the thresholds for each tier, shown in Table C1, based on thresholds 
used internationally and cost-sharing arrangements of U.S. commercial plans.162 The “standard” QALY 
thresholds are not absolute, and some products may be placed on a “preventive list.” Drugs for rare 
conditions (“ultra-orphan” drugs) are subject to different, more liberal “special case” thresholds (Table 
C1). Even after this assessment, a product’s placement on the VBRx may still depend on extenuating 
clinical or societal circumstances. 
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Table C1 
Tier Standard Thresholds Special Case Thresholds 
Preventive tier -- not applicable -- -- not applicable -- 
Tier 1: Highly cost-
effective 
<$10,000 per QALY <$50,000 per QALY 
Tier 2: cost-effective $10,000 to $50,000 per QALY $50,000 to $150,000 per QALY 
Tier 3: somewhat cost-
effective 
$50,000 to $150,000 per QALY >$150,000 per QALY 
Tier 4: minimally cost-
effective 
>$150,000 per QALY or insufficient 
evidence to determine cost-
effectiveness 
Insufficient evidence to 
determine cost-effectiveness 
Source: Sullivan et al., 2015164 
Table C2 
The VBRx copayments vary by tier (Table C2). Products designated for 
the preventive tier have no cost sharing. Products on the other tiers 
have fixed cost sharing amounts that increase on each successive tier 
– that is, as the assessed cost-effectiveness of a product decreases, 
the out-of-pocket cost to the consumer increases.  
Source: Sullivan et al., 2015164 
For Premera, the VBRx program enabled an initial cost shift to members without affecting adherence in 
high value drug classes in the first year following implementation.165 The plan’s pharmacy payments 
dropped by about 3% per member per month (PMPM) compared to payments in the prior year.164 
Compared to simulated PMPM amounts based on historical trends, which were intended to model a 
counterfactual where the VBRx had not been implemented, the estimated savings were about 11 
percent PMPM.164  
The impact on member and overall health plan costs has not been determined and is unclear.164 
Consumers experienced a range of effects under the VBRx. Overall, group members saw their out-of-
pocket costs increase by 12 percent for all medications, but patient with diabetes, hypertension, and 
dyslipidemia experienced lower overall increases across all of their medications (5%, 8%, and 2%, 
respectively).164 However, the plan increased cost-sharing levels simultaneous to the launch of the VBRx, 
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Tier Co-payment 
Preventive $0 
Tier 1 $20 
Tier 2 $40 
Tier 3 $65 
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which contributed to a cost shift: high-utilizers experienced both co-payment decreases and increases, 
while low-utilizers generally paid higher out-of-pocket costs.166 
Subscribers’ responses to the cost shift varied, with some shifting to lower-cost drugs, and some paying 
the higher costs and continuing on original medications.166 Skipping medications, cutting tablets, or 
other strategies to reduce out-of-pocket costs were purportedly rare.166 Overall use and adherence 
increased among hypertension patients; effects for other groups were not statistically significant.166 
Although Premera intended to convey the value of products through variation in copayment levels, 
participants in focus groups convened by the organization were generally unaware or lacked 
understanding regarding the VBRx.167 Members of the Premera VAC and others involved in the 
development of the VBRx characterized these focus group participants as “positive” toward the use of 
evidence and efforts to hold down costs and encourage consumers to take more responsibility for their 
own health, but noted that they also wanted to know who determined the value of drugs.166,167 
HOW MIGHT BROADER USE OF PROGRAMS LIKE VBRX INFLUENCE INNOVATION IN DRUGS 
OR MEDICAL DEVICES? 
VBID is a concept with significant traction among state and federal policymakers, who appear to view it 
as conceptually appealing even though implementation has been limited to date. Many stakeholders 
have voiced support for VBID, and Section 2713(a) of the Affordable Care Act explicitly encourages 
development of guidelines for VBID programs. There has been some controversy about the attention 
given to VBID, in part due to the limited evidence available for assessment of the potential effects on 
clinical outcomes, other benefits, and costs from the perspective of patients, third-party payers, and 
plan sponsors.168 
Despite its high profile, uptake of VBID has been slow among payers and plan sponsors. To date, most 
efforts in the U.S. have been limited in scope compared to the Premera VBRx program. Most payers 
apply VBID programs to a very small number of therapeutic classes. One effort that was broader in 
scope was a value-based formulary called RxImpact developed by Humana, where drugs were placed 
into one of four groups based on the insurer’s assessment of the ability of a drug to avoid more serious 
medical events (e.g., hospitalizations) and the length of time before its use might affect total medical 
expenditures for the plan. The cost-sharing structure did not vary for different patients, but instead the 
                                                          
166
 Garrison, L. (2013). Are the Europeans doing a better job evaluating drugs than US P&T committees? The gap 
between CER and HTA. AMCP Foundation Symposium: Transplanting European Health Technology Assessment 
(HTA) to America? What’s wrong with our Version? San Antonio, TX.  
167
 Sullivan, S. D., Yeung, K., Vogeler, C., Ramsey, S. D., Wong, E., Murphy, C. O., . . . Watkins, J. B. (2015). Design, 
implementation, and first-year outcomes of a value-based drug formulary. Journal of Managed Care & 
Specialty Pharmacy: JMCP, 21(4), 269-269-275.  
168
 Choudhry, N. K., Rosenthal, M. B., & Milstein, A. (2010). Assessing the evidence for value-based insurance 
design. Health Affairs, 29(11), 1988-1994. doi:10.1377/hlthaff.2009.0324 
 
 
Page | 78 
 
plan paid a fixed allowance per prescription depending on the group the drug was in, and the patient 
paid any difference between the allowance and the drug’s retail cost.169 
Chernew and colleagues (2007) list a number of challenges and concerns that may dissuade payers and 
plan sponsors from broader adoption of programs like VBRx, including:  
 Cost of implementation; 
 Cost of increased use of drugs relative to potential benefits; 
 Lack of access to data/information necessary to determine appropriate cost-sharing levels; 
 Lack of sufficiently detailed data/research evidence for all groups and/or conditions; 
 Human resources and ethics concerns (e.g., “favoring” certain people with lower cost sharing); 
 HIPAA/privacy concerns with high levels of information about specific patients changing hands 
to administer the program; 
 Legal barriers (e.g., government program restrictions on financial incentives for patients); 
 Concerns about affecting incentives for patients to use products with lower total costs to the 
payer or system (such as generic drugs) if cost sharing is also reduced for products with higher 
total costs, and; 
 Possibility of adverse selection, if a benefit viewed as particularly generous for people with a 
particular condition attracts those people to the employer/health plan. 170 
From the perspective of a third-party payer, plan sponsor, or self-insured organization – all groups for 
which total costs of care are most relevant – higher levels of churn/turnover among plan participants 
may discourage use of VBID if they believe they will incur higher total costs for drug benefits without 
capturing the future benefits, such as better health outcomes and cost savings.171 Payers with less 
participant turnover, such as Medicare or the Veterans’ Administration, may have longer investment 
horizons. Experts consulted for this study noted that private payers may also be taking longer 
perspectives than may have assumed in the past.172 
                                                          
169
 Lewis, C. (2007). Will value-based pharmacy design take off? National managed care outlook. HealthLeaders-
Interstudy. 
170
 Chernew, M. E., Rosen, A. B., & Fendrick, A. M. (2007). Value-based insurance design. Health Affairs, 26(2), 
w195-w203. Retrieved from http://content.healthaffairs.org/content/26/2/w195.abstract 
171
 Choudhry, N. K., Rosenthal, M. B., & Milstein, A. (2010). Assessing the evidence for value-based insurance 
design. Health Affairs, 29(11), 1988-1994. doi:10.1377/hlthaff.2009.0324 
172
 These experts offered several reasons why plans may be taking on longer investment horizons: (1) they may 
have lower levels of expected turnover of plan participants, related to people holding onto jobs longer both during 
and immediately following the recent recession; (2) consolidation in the marketplace has led to larger health plans 
and increased the likelihood that people will remain in a plan operated by the insurer, even if they change jobs, 
and; (3) many insurers participate in multiple markets, including employer-based, Marketplace exchanges 
(individual), and Medicare Advantage, so they may cover the same person at multiple points during his/her 
lifetime, even if there are gaps in coverage. 
 
 
Page | 79 
 
Studies indicate that VBID initiatives are associated with modest increases in adherence to targeted 
therapies, although effects on costs and clinical outcomes are less clear.173 Consequently, for payers, 
drug spending tends to increase, while effects on non-medication spending and total spending are 
unclear. For example, Blue Cross, Blue Shield of North Carolina attempted a VBID plan in 2008, which 
eliminated copayments for generic medications and lowered copays for brand-name drugs; though 
patient adherence improved and hospital admissions decreased, there were no changes in emergency 
department use or in health expenditures and early experience was not cost-neutral.174 A recent review 
of empirical evidence from VBID programs found that the plans that achieved the best patient 
adherence were those that targeted high-risk patient subgroups (for whom cost is a significant barrier), 
had more generous reductions in out of pocket costs, offered wellness programs, and were only 
available for medication ordered by mail.175 
Quantifying the return for payers from VBID is challenging. Overall, for the patient and payer combined, 
evidence suggests that drug spending may increase without a significant change in non-medication or 
total spending.176 However, observers have noted that changes in adherence attributed to VBID 
programs tend to be modest, the evidence base is small, and the methods often not very rigorous.177 
Some observers have suggested that VBID plans may not achieve savings because patients in 
commercial plans tend to be less price sensitive, and the high-cost events that these programs may seek 
to avoid, such as emergency room visits and hospital stays, are relatively rare – so it is harder to offset 
the extra costs from lower copayments.178 
PBMs have sometimes expressed doubts about VBID, with some viewing it as a higher cost method to 
improve adherence than other strategies.177 A 2007 Health Leaders-Interstudy report quoted Bob Craig, 
an executive from Medco Health Solutions, saying that, with regard to VBID, “[e]mployers want to know 
the [return on investment] as well as the time required for the healthcare payment on the 
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investment.”179 Mr. Craig noted that how an employer or other plan sponsor or designer views VBID for 
a particular set of patients may depend on the quality of the available evidence used to inform decisions 
about “value,” the investment horizon of the employer or payer, and the underlying benefit philosophy 
and expectations.179 He added that “[VBID] may prove to be less well suited for employers with younger 
workforces or higher turnover.”179 Some of the experts consulted for this project echoed these 
sentiments. 
Both patients and health care providers must buy into the VBID concept.180 VBID raises difficult 
questions that require value judgments. Who decides what constitutes “value” for a particular plan is 
clearly important and potentially controversial. Some may disagree about which evidence is best or 
conclusions based on that evidence – for example, the controversy over the U.S. Preventive Task Force’s 
recommendations concerning breast cancer screening highlight that major differences of opinion are 
likely to remain even in cases where decisions are evidence-based. Concerns about value judgments, 
and the challenges of obtaining patient and provider buy-in, are likely to be magnified in the context of 
specialty drugs.181 A systematic review of the literature on specialty drug therapies for rheumatoid 
arthritis, multiple sclerosis, and breast cancer concluded that these therapies offered significant 
potential benefits for patients, but achieving the best outcomes and most cost-effective use required 
identifying the most effective product(s) and the most appropriate patients within each category.182 
Other research indicates that specialty drugs may confer somewhat greater benefits than traditional 
drugs, but at higher costs and with considerable variation in costs per QALY.183 
For programs like Premera’s VBRx to succeed on a broader scale, plans and plan sponsors will require 
access to data and empirical evidence about clinical benefits and costs, both monetary and non-
monetary. One potential limitation is that limited availability of evidence from cost-effectiveness 
assessments may prevent optimal placement of drugs.184 Some developers such as Novartis, BMS, 
Amgen, Lilly, and Sanofi-Aventis reportedly adapted European models for use in the U.S. context or 
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otherwise cooperated with the Premera VAC.185 However, the authors of a recent article describing the 
program’s roll-out and early results were “concerned by the frequency with which [the VAC’s] requests 
for economic data [from manufacturers] were either denied or ignored,” some of which may have been 
attributable to manufacturers’ perceptions about the legality of sharing this information.186 
The willingness of manufacturers to assist in value-based assessment processes may depend on the 
extent to which they view the processes as transparent, fair, and, ultimately, beneficial in terms of 
placement of at least some of their most important products. Given the general sentiments expressed in 
studies of existing VBID programs that more and better data are needed, expansion of VBID programs 
would likely lead to more pressures on developers to collect and share data. In theory, more data 
requires more studies and higher costs of product development and/or sale, potentially reducing 
developers’ expected return on investment (EROI). However, experts consulted during this study noted 
that payers worldwide are already demanding more and better data for decision-making, so it is not 
clear whether more use of VBID would dramatically increase costs of new drug and device development 
for manufacturers relative to current trends. Current trends also may already reflect a growing emphasis 
on value in other reimbursement approaches, not just VBID. Theoretically, if more plans explicitly 
incorporate value into their assessments that determine availability of products and cost sharing for 
patients, developers and manufacturers would be incentivized to invest in products that they believe 
payers will view as innovative (i.e., meeting more significant unmet needs and/or providing greater net 
health benefits relative to existing treatments) and potentially consumer-welfare enhancing. 
In lieu of manufacturer participation in assessment processes, plans will need to develop expertise and 
capacity internally to conduct value assessments, as Premera did, but that will likely raise administrative 
costs for the payer. The Premera experience suggests that local champions at the plan, accompanied by 
health economists and others who will provide expertise, are important for creation and sustainability of 
a VBID program. 
VBID explicitly implicates changes in out-of-pocket payments for patients, but it is less clear that formal 
assessments of value would lead to changes in sales prices for manufacturers/developers. Rebates and 
other discounts negotiated between payers and manufacturers or other sellers are almost always kept 
secret, and the Premera VBRx program is no exception. In theory, value-based methods of determining 
payment amounts should decrease payment amounts (at least the payer’s share) for novel products that 
are not innovative or cost-reducing, while increasing payment amounts for innovative products, 
commensurate with the level of additional benefit. The VBRx uses cost-effectiveness thresholds to 
determine tier placement, but with the caveat that a product’s placement on the VBRx may still depend 
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on extenuating clinical or societal circumstances. Therefore, it is unclear how closely Premera’s concept 
of value aligns with the definition of innovation used in this project, which is a function of the extent to 
which a drug or device addresses a disease or condition for which there is a substantive (i.e., non-trivial) 
unmet or inadequately met need, and whether, and to what extent, the new product offers clinically 
meaningful benefits compared to existing treatments. 
Theoretically, broader use of VBID and value-based formularies also would lead to less utilization of 
products and services with little value added, and more utilization for products with higher value. 
Assuming payments and utilization change in this manner, VBID may potentially increase incentives to 
invest in R&D aimed at products that are more likely to be deemed as substantial and radical 
innovations. The modest effects on utilization in the few VBID programs assessed to date do not suggest 
major changes in health plans’ negotiating power compared to manufacturers solely because of VBID, 
but the existing evidence is insufficient to draw any definitive conclusions about broader applications. 
CONCLUSION 
Further evaluation of programs such as Premera’s VBRx is needed to determine how broader use may 
ultimately affect incentives in the marketplace that affect the return on investment for developers of 
new products, including sales volume, sales prices, and development costs. Longer study periods may 
help to tease out delayed effects on spending, health outcomes, or other factors. A broader focus on 
total costs to a health plan is necessary. An assessment of spillover effects is also important; where VBID 
applies to a particular category of services, such as drugs, but not others, there may be interactions with 
other reimbursement systems for other services.187 To date, the evidence base from Premera’s VBRx 
and VBID programs more broadly – at least that available in broadly-accessible public sources – is 
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APPENDIX D: NICE (UK) PERFORMANCE-BASED REIMBURSEMENT FOR VELCADE® 
BACKGROUND - NICE AND ITS ROLE 
The National Institute for Health and Care Excellence (NICE) was established in 1999 as the National 
Institute for Clinical Excellence, a special health authority with the explicit objectives of reducing 
variation in the availability and quality of treatments and care in the UK National Health Service (NHS), 
promoting the diffusion and uptake of new technologies, setting quality standards, and improving 
efficiency.188 In 2005 NICE was merged with the Health Development Agency, the development of public 
health guidance was added to its remit, and its name changed to the National Institute for Health and 
Clinical Excellence.  
Since January of that year the NHS in England and Wales has been legally obliged to provide funding for 
those medicines and treatments recommended by NICE, within three months of the release of the 
relevant NICE Guidance.189 This was, at least in part, the result of an effort to address well-publicized 
“postcode lottery” anomalies in which certain less-common treatments were funded in some parts of 
the UK but not in others, due to local decision-making and fundholding within the NHS.189 
Subsequently, in April 2013 NICE was established in primary legislation, becoming a Non-Departmental 
Public Body (NDPB) accountable to the Department of Health, but operationally independent of 
government.  At that time the name was changed again, to the National Institute for Health and Care 
Excellence, reflecting the acquisition of additional responsibility for developing guidance and quality 
standards in social care.190  
Today NICE’s role involves developing and promulgating guidance in four areas:  
 the use of health technologies within the NHS (such as the use of new and existing medicines, 
treatments and procedures);  
 clinical practice (guidance on the appropriate treatment and care of people with specific 
diseases and conditions);  
 guidance for public sector workers on health promotion and ill-health avoidance; and  
 guidance for social care services and users.  
NICE appraisals of medicines and other health technologies are based primarily on assessments of 
comparative clinical effectiveness and cost–effectiveness in various circumstances. Importantly, while 
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the NICE Board sets the organization’s strategic priorities and policies, NICE guidance and other 
recommendations are made by independent committees.  
The status of NICE guidance is reinforced in the NHS Constitution, which states that patients have the 
right to any drugs and treatments recommended by NICE for use in the NHS, if the physician responsible 
for the patient’s care considers them to be clinically appropriate.191 
NICE’S APPRAISAL OF VELCADE (BORTEZOMIB)  
Bortezomib is an anti-neoplastic agent belonging to a novel class of drugs known as proteasome 
inhibitors. In 2005 bortezomib held UK marketing authorization as monotherapy for the treatment of 
progressive multiple myeloma in patients who have received at least one prior therapy, and who have 
undergone, or are unsuitable for, bone marrow transplantation.  
NICE’s appraisal was based largely on evidence from the APEX (Assessment of Proteasome Inhibition for 
Extending Remissions) trial, at that time the largest published randomized controlled trial of the 
treatment of relapsed multiple myeloma. The trial compared response rate, time to disease progression 
and overall survival in patients treated with bortezomib with those treated with high dose 
dexamethasone (HDD), the standard of care at the time for patients who had relapsed following initial 
treatment for multiple myeloma.192 Patients in the bortezomib arm experienced statistically significant 
improvements in time to disease progression and overall survival, and the NICE APPraisal Committee 
concluded that bortezomib monotherapy was more clinically effective than HDD monotherapy for the 
treatment of relapsed multiple myeloma.193 
Bortezomib was not found to be comparatively cost effective however; for patients at first relapse, the 
ICER for bortezomib over HDD was estimated at £31,000 per life year gained, or £38,000 per 
QALY.193,194,195 The ICER threshold in England is generally in the range of £20,000 - £30,000,196 unless 
certain ‘end-of-life criteria’ apply.197,198,199 
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As noted in the Task 3a report, we define a healthcare technology to be a consumer welfare-enhancing 
innovation if it meets our criteria for innovation and generates consumer surplus.200 NICE’s appraisal 
committee concluded that despite evidence that bortezomib was more clinically effective than HDD, the 
opportunity costs of its acquisition and diffusion would exceed the anticipated value of the projected 
incremental benefits of treatment. Thus in this circumstances bortezomib would not meet the definition 
of a consumer welfare-enhancing innovation. 
THE MANUFACTURER’S RESPONSE – A RISK SHARING PROPOSAL 
Wishing to avoid a negative recommendation by NICE, Janssen-Cilag put forward a proposal to the UK 
Department of Health (DoH) for a novel, performance-based, risk-sharing arrangement (referred to as a 
Patient Access Scheme or PAS). The proposal included a provision for treatment cessation in patients 
failing to achieve a pre-defined response (based on measuring serum levels of M-protein, a tumor 
marker indicative of tumor shrinkage and an accepted surrogate measure of disease progression), and 
reimbursement to the NHS for cases of treatment failure. For each patient failing to achieve sufficient 
tumor shrinkage as measured by a reduction in serum M protein of 50% or more, Janssen-Cilag agreed 
to provide the NHS with a refund equal to the cost of that patient’s treatment, or the same amount of 
the drug for another patient, at no charge to the NHS.195,201  
Following the DoH’s in-principle acceptance of the risk-sharing arrangement, the drug was reanalyzed by 
NICE. After analyzing various new economic considerations brought about by the risk-sharing 
arrangements, the anticipated ICER was calculated to be £20,700 and the medicine was recommended 
for use within the NHS.201  
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The final guidance issued by NICE specified that: 
Bortezomib monotherapy is recommended as an option for the treatment of progressive multiple 
myeloma in people who are at first relapse having received one prior therapy and who have undergone, 
or are unsuitable for, bone marrow transplantation, under the following circumstances: 
 the response to bortezomib is measured using serum M protein after a maximum of four cycles 
of treatment, and treatment is continued only in people who have a complete or partial response 
(that is, reduction in serum M protein of 50% or more or, where serum M protein is not 
measurable, an appropriate alternative biochemical measure of response) and 
 the manufacturer rebates the full cost of bortezomib for people who, after a maximum of four 
cycles of treatment, have less than a partial response (as defined above). 
DISCUSSION 
Risk-sharing arrangements (RSAs) in healthcare between payers and manufacturers are not new. Purely 
financial RSAs, under which rebates are paid or prices reduced where utilization or expenditure exceed 
pre-determined thresholds,202 have been part of the reimbursement landscape in a number of countries 
for some time.203,204 More recent, however, is the advent of the performance-based RSA, where 
payment is contingent on the benefit of a technology being monitored in individual patients within a 
specified population over a pre-determined period (reflecting actual clinical use), and with the price 
paid, or amount of reimbursement based on the demonstration of a pre-specified response to 
treatment. 
In the UK, PAS are negotiated within the framework of the general voluntary agreement between the 
DoH and the pharmaceutical industry, known as the Pharmaceutical Price Regulation Scheme (PPRS). 
The PPRS underwent substantial reform in 2009, following an evaluation by the Office of Fair Trading 
(OFT) that recommended replacing existing profit and price controls with a more value-based approach 
to pricing.205 As a result of the OFT report, the new PPRS defined a clear typology of PASs in the UK, 
consisting of two main types: financially based schemes and outcome-based schemes. In the first case, 
the company does not alter the list price of the medicine but offers discounts or rebates linked to 
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several variables, such as the number of patients treated, or the response of these patients to the 
treatment. In the second case, the outcome-based schemes have four different subtypes: proven value, 
price increase, expected value rebate, and risk sharing.206 Figure D1 illustrates that typology. 
Figure D1: Typology of Performance-based Patient Access Schemes in the UK 
 
Source: Carlson et al (2010)207 
The Velcade PAS was not the first arrangement to involve performance-based risk-sharing in the UK (see 
Figure D2). In 2002 an agreement was reached to facilitate access to a number of multiple sclerosis (MS) 
medications within the NHS, subject to data collection to support prior estimates of cost-effectiveness. 
Uncertainty about the long-term cost-effectiveness of beta interferons (Avonex, Betaferon, Rebif) and 
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glatiramer (Copaxone) for MS had led NICE to recommend against their use in the NHS.208  Under an 
arrangement reached with the manufacturers, the DoH agreed to allow the prescribing of these drugs 
according to the Association of British Neurologists’ 2001 guidelines, conditional on the development of 
a 10-year monitoring study that would collect data on the progression of disease in treated patients. If 
any product failed to show benefits consistent with projections made at the outset of the arrangement, 
the subsequent price to the NHS would be reduced to restore cost effectiveness to a benchmark of 
£36,000 per quality adjusted life year (QALY) evaluated over a 20-year horizon.209 Aspects of the design 
of the arrangement were subsequently criticized, including the time horizon, choice of outcome 
measure, and use of historical controls. Concerns were also expressed about data governance issues, 
and the costs and effort involved in data collection.208,210,211,212 
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Figure D2: Different types of performance-based reimbursement 
 
Source:  Coulton et al, 2010213 
The Velcade PAS was however, the first to involve a manufacturer rebate for treatment failure. Because 
the NHS would pay for the drug only for those patients who demonstrated an adequate response to 
treatment, the PAS effectively amounted to both a performance guarantee and a substantial price 
discount.214 , 215  However, unlike a simple discount arrangement or price-volume agreement, the 
manufacturer has a strong incentive to maximize the number of patients who respond, not merely the 
number treated or the quantity of drug sold.214 The result is potentially positive for all stakeholders; the 
manufacturer gains market access and maintains its list price, the latter being extremely valuable as 
many countries reference their prices against those in the UK;216 patients gain access to a therapy that 
might otherwise not be subsidized, and may also benefit from more active, protocol-driven follow-up; 
and the payer benefits from reduced budgetary risk, albeit with the added effort and cost of establishing 
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and maintaining a suitable patient tracking system—a burden which can, depending on the nature of 
the performance metric, prove to be quite substantial.215  
While to date there has been no formal evaluation of the Velcade PAS, both the MS and Velcade 
examples highlight the practical challenges of performance-based or “payment by results” 
reimbursement schemes. To be workable there should be a clearly defined, objective metric of 
treatment effect (performance) that is either a direct measure of clinical outcome (such as survival or 
cure) or a well-accepted surrogate endpoint that closely corresponds to or reliably predicts the desired 
treatment effect and is unaffected by other treatments. The clinical outcome measure should not be 
confounded by patient characteristics or the use of concomitant treatments that would obscure the 
effect of the index therapy, unless these issues can be adjusted for in an analysis. The availability of a 
validated and reliable well-accepted surrogate outcome, such as the serum M-protein level in the 
Velcade PAS, was a clear advantage, and limiting the arrangement to second-line treatment—patients in 
whom prior treatment had failed—reduced the likelihood that the results would be contaminated by 
other treatments.217  
Nevertheless Neumann et al (2011) found that performance-based risk-sharing arrangements for 
pharmaceuticals are “appealing in theory but hard in practice.”218 For the manufacturer there is the 
uncertainty about whether the drug will perform adequately, and whether the outcomes achieved in a 
highly controlled clinical trial environment can be replicated in real-life settings.219 For payers there is 
burden of measuring and monitoring patient progress, and there may also be the challenging prospect 
of having to withdraw coverage of a drug either entirely, or in individual patients, depending on the 
nature of the RSA. Although the PAS has become an integral part of the UK pharmaceutical 
environment, since the Velcade example the vast majority have been financially based arrangements. 
These are perceived as being far simpler to administer than the outcome- or performance-based PAS.220  
There are currently 40 drugs with 55 approved PAS in place in the UK;221 of these the Velcade PAS is the 
only current performance-based scheme.220 
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HOW MIGHT BROADER USE OF ARRANGEMENTS SUCH AS THE VELCADE PAS INFLUENCE 
INNOVATION IN DRUGS OR MEDICAL DEVICES?  
Whether performance-based RSAs such as the Velcade PAS influence incentives to innovate remains 
unclear. Velcade was demonstrated to offer a clinical benefit over existing treatment options for 
multiple myeloma, but at a net cost deemed to represent inadequate value for money relative to the 
expected health gains. By this definition, at the original price proposed, Velcade did not meet the 
definition of an innovation that enhances consumer welfare in the United Kingdom. By modifying the 
effective price, and by inference, the cost effectiveness of the drug, the PAS modified this calculus, 
allowing Velcade to meet the definition of a substantive innovation, albeit with an effect on the 
manufacturer’s expected return-on-investment (EROI). While the PAS likely reduced the EROI relative to 
unrestricted coverage, the EROI would almost certainly be better with the PAS than with a negative 
recommendation from NICE. The PAS also enabled the manufacturer to maintain its list price for the 
drug in the UK, a country from which prices are referenced all around (and beyond) Europe, thereby 
helping to preserve EROI on sales made elsewhere.  
The conceptual model presented in this research project cast EROI as a proxy for incentive to innovate 
and posited that current returns on investment are viewed as indicative of potential future returns. Our 
analysis has shown that reimbursement policies and practices can affect EROI (or ROI) directly by 
establishing a particular payment level, which in turn affects average sales price; by setting a volume of 
sales at that payment level; and by influencing the seller’s costs associated with development, 
manufacture, or sale of a healthcare technology. Moreover, as noted previously, reimbursement policies 
can also influence EROI/ROI indirectly by establishing different incentives for the various stakeholders 
which can, in turn, impact effective price, volume and, in some cases, seller costs.  
A Velcade PAS-style scheme is effectively a value-based method of determining an overall payment 
amount that averts payer costs for novel products that are not innovative, while increasing payment 
amounts for innovative products, commensurate with the level of additional benefit.  
Theoretically, broader use of outcomes-based reimbursement would lead to lower returns on products 
and services offering little value added, higher returns for products with higher value, and greater clarity 
where value-added is uncertain—albeit at the cost (and risk) of implementing the outcomes-based 
reimbursement scheme. This could potentially increase incentives to invest in R&D aimed at products 
more likely to be deemed substantial or radical innovations—at the very least it may stimulate 
investment in the identification and validation of biomarkers that could be tendered as proxies for the 
clinical outcomes of interest when outcomes-based reimbursement is under consideration. 
In light of the lack of measured evaluation of experience to date, coupled with the previously identified 
challenges in effective implementation of outcomes-based arrangements, the Velcade case provides 
insufficient evidence from which to draw definitive conclusions about the impact of the approach on 
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CONCLUSION 
The Velcade PAS in the UK was the first reimbursement protocol implemented in the UK to involve 
rebates for treatment failure. NICE’s appraisal committee concluded that the opportunity costs of 
acquisition and diffusion would exceed the anticipated value of the projected incremental benefits of 
treatment. The PAS, a performance-based, risk-sharing arrangement, included a provision for treatment 
cessation in patients failing to achieve a pre-defined response, and reimbursement to the NHS for cases 
of treatment failure. At the original price proposed, Velcade did not meet the definition of an innovation 
that enhances consumer welfare in the UK. The PAS changed the effective price and allowed Velcade to 
meet the definition of a substantive innovation, albeit with an effect on the manufacturer’s expected 
return-on-investment (EROI). It is unclear whether performance-based RSAs such as the Velcade PAS 
influence incentives to innovate, in part because of the lack of measured evaluation of this program and 
because of the challenges of designing and administering an outcome- or performance-based PAS. The 
vast majority of PAS in the UK since the Velcade example have been financially based arrangements. 
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